1
|
de-Torres JP, Casanova C, Marín JM, Cabrera C, Marín M, Ezponda A, Cosio BG, Martínez C, Solanes I, Fuster A, Calle M, Peces-Barba G, Gotera C, Feu-Collado N, Marin A, Alcaide AB, Sangro M, Bastarrika G, Celli BR. Impact of Applying the Global Lung Initiative Criteria for Airway Obstruction in GOLD Defined COPD Cohorts: The BODE and CHAIN Experience. Arch Bronconeumol 2024; 60:10-15. [PMID: 37925245 DOI: 10.1016/j.arbres.2023.10.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2023] [Revised: 09/26/2023] [Accepted: 10/05/2023] [Indexed: 11/06/2023]
Abstract
INTRODUCTION The Global Lung Function Initiative (GLI) has proposed new criteria for airflow limitation (AL) and recommends using these to interpret spirometry. The objective of this study was to explore the impact of the application of the AL GLI criteria in two well characterized GOLD-defined COPD cohorts. METHODS COPD patients from the BODE (n=360) and the COPD History Assessment In SpaiN (CHAIN) cohorts (n=722) were enrolled and followed. Age, gender, pack-years history, BMI, dyspnea, lung function measurements, exercise capacity, BODE index, history of exacerbations and survival were recorded. CT-detected comorbidities were registered in the BODE cohort. The proportion of subjects without AL by GLI criteria was determined in each cohort. The clinical, CT-detected comorbidity, and overall survival of these patients were evaluated. RESULTS In total, 18% of the BODE and 15% of the CHAIN cohort did not meet GLI AL criteria. In the BODE and CHAIN cohorts respectively, these patients had a high clinical burden (BODE≥3: 9% and 20%; mMRC≥2: 16% and 45%; exacerbations in the previous year: 31% and 9%; 6MWD<350m: 15% and 19%, respectively), and a similar prevalence of CT-diagnosed comorbidities compared with those with GLI AL. They also had a higher rate of long-term mortality - 33% and 22% respectively. CONCLUSIONS An important proportion of patients from 2 GOLD-defined COPD cohorts did not meet GLI AL criteria at enrolment, although they had a significant burden of disease. Caution must be taken when applying the GLI AL criteria in clinical practice.
Collapse
Affiliation(s)
- Juan P de-Torres
- Pulmonary Department, Clínica Universidad de Navarra, Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
| | - Ciro Casanova
- Pulmonary Department-Research Unit, Hospital Universitario Nuestra Señora de Candelaria, CIBERES, ISCIII, Universidad de La Laguna, Tenerife, Spain
| | - José M Marín
- Pulmonary Department, Hospital Universitario Miguel Servet, IIS Aragon & CIBERES, University of Zaragoza, Zaragoza, Spain
| | - Carlos Cabrera
- Pulmonary Department, Hospital Universitario Doctor Negrín, Las Palmas, Spain
| | - Marta Marín
- Pulmonary Department, Clínica Universidad de Navarra, Pamplona, Spain; Hospital Universitario Lozano Blesa, Zaragoza, Spain
| | - Ana Ezponda
- Radiology Department, Clínica Universidad de Navarra, Pamplona, Spain
| | - Borja G Cosio
- Hospital Universitario Son Espases, Instituto de Investigación Sanitaria de Baleares (IdISBa), Palma, Mallorca, Spain; Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
| | - Cristina Martínez
- Instituto de Investigación Sanitaria del Principado de Asturias (ISPA-FINBA), Spain
| | - Ingrid Solanes
- Pulmonary Department, Hospital Santa Creu i Sant Pau, Universidad Autónoma de Barcelona, Barcelona, Spain
| | - Antonia Fuster
- Pulmonary Department, Hospital Universitario Son Llatzer, Palma de Mallorca, Spain
| | - Myriam Calle
- Department of Respiratory Medicine, Hospital Clínico San Carlos, Department of Medicine, School of Medicine, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain
| | - Germán Peces-Barba
- Department of Respiratory Medicine, Hospital Universitario Fundación Jiménez Díaz, CIBERES, Madrid, Spain
| | - Carolina Gotera
- Department of Respiratory Medicine, Hospital Universitario Fundación Jiménez Díaz, CIBERES, Madrid, Spain
| | - Nuria Feu-Collado
- Pulmonary Department, Hospital Universitario Reina Sofía, Instituto Maimónides de Investigación Biomédica de Córdoba, Universidad de Córdoba, Córdoba, Spain
| | - Alicia Marin
- Pulmonary Department, Hospital Universitario German Trias y Pujol, Barcelona, Spain
| | - Ana Belén Alcaide
- Pulmonary Department, Clínica Universidad de Navarra, Pamplona, Spain
| | - Matilde Sangro
- Pulmonary Department, Clínica Universidad de Navarra, Pamplona, Spain
| | - Gorka Bastarrika
- Radiology Department, Clínica Universidad de Navarra, Pamplona, Spain
| | - Bartolome R Celli
- Pulmonary Department, Brigham and Women's Hospital, Boston, MA, United States
| |
Collapse
|
2
|
Giménez‐Capitán A, Sánchez‐Herrero E, Robado de Lope L, Aguilar‐Hernández A, Sullivan I, Calvo V, Moya‐Horno I, Viteri S, Cabrera C, Aguado C, Armiger N, Valarezo J, Mayo‐de‐las‐Casas C, Reguart N, Rosell R, Provencio M, Romero A, Molina‐Vila MA. Detecting ALK, ROS1, and RET fusions and the METΔex14 splicing variant in liquid biopsies of non-small-cell lung cancer patients using RNA-based techniques. Mol Oncol 2023; 17:1884-1897. [PMID: 37243883 PMCID: PMC10483610 DOI: 10.1002/1878-0261.13468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2023] [Revised: 04/28/2023] [Accepted: 05/26/2023] [Indexed: 05/29/2023] Open
Abstract
ALK, ROS1, and RET fusions and MET∆ex14 variant associate with response to targeted therapies in non-small-cell lung cancer (NSCLC). Technologies for fusion testing in tissue must be adapted to liquid biopsies, which are often the only material available. In this study, circulating-free RNA (cfRNA) and extracellular vesicle RNA (EV-RNA) were purified from liquid biopsies. Fusion and MET∆ex14 transcripts were analyzed by nCounter (Nanostring) and digital PCR (dPCR) using the QuantStudio® System (Applied Biosystems). We found that nCounter detected ALK, ROS1, RET, or MET∆ex14 aberrant transcripts in 28/40 cfRNA samples from positive patients and 0/16 of control individuals (70% sensitivity). Regarding dPCR, aberrant transcripts were detected in the cfRNA of 25/40 positive patients. Concordance between the two techniques was 58%. Inferior results were obtained when analyzing EV-RNA, where nCounter often failed due to a low amount of input RNA. Finally, results of dPCR testing in serial liquid biopsies of five patients correlated with response to targeted therapy. We conclude that nCounter can be used for multiplex detection of fusion and MET∆ex14 transcripts in liquid biopsies, showing a performance comparable with next-generation sequencing platforms. dPCR could be employed for disease follow-up in patients with a known alteration. cfRNA should be preferred over EV-RNA for these analyses.
Collapse
Affiliation(s)
- Ana Giménez‐Capitán
- Pangaea Oncology, Laboratory of OncologyDexeus University HospitalBarcelonaSpain
| | - Estela Sánchez‐Herrero
- Atrys HealthBarcelonaSpain
- Liquid Biopsy LaboratoryBiomedical Sciences Research Institute Puerta de Hierro‐MajadahondaMadridSpain
| | - Lucía Robado de Lope
- Liquid Biopsy LaboratoryBiomedical Sciences Research Institute Puerta de Hierro‐MajadahondaMadridSpain
| | | | - Ivana Sullivan
- Dr Rosell Oncology InstituteQuirón Dexeus University HospitalBarcelonaSpain
- Hospital de la Santa Creu i Sant PauBarcelonaSpain
| | - Virginia Calvo
- Medical Oncology DepartmentHospital Universitario Puerta de Hierro‐MajadahondaSpain
| | - Irene Moya‐Horno
- Hospital Universitario General de Cataluña Grupo QuirónSant Cugat del VallésSpain
| | | | | | - Cristina Aguado
- Pangaea Oncology, Laboratory of OncologyDexeus University HospitalBarcelonaSpain
| | - Noelia Armiger
- Pangaea Oncology, Laboratory of OncologyDexeus University HospitalBarcelonaSpain
| | - Joselyn Valarezo
- Pangaea Oncology, Laboratory of OncologyDexeus University HospitalBarcelonaSpain
| | | | | | - Rafael Rosell
- Dr Rosell Oncology InstituteQuirón Dexeus University HospitalBarcelonaSpain
- Hospital Germans Trias i PujolHealth Sciences Institute and Hospital (IGTP)BarcelonaSpain
| | - Mariano Provencio
- Medical Oncology DepartmentHospital Universitario Puerta de Hierro‐MajadahondaSpain
| | - Atocha Romero
- Liquid Biopsy LaboratoryBiomedical Sciences Research Institute Puerta de Hierro‐MajadahondaMadridSpain
- Medical Oncology DepartmentHospital Universitario Puerta de Hierro‐MajadahondaSpain
| | | |
Collapse
|
3
|
Crabtree Ramírez B, González Hernández LA, Cabrera C, Del Río C, González Rodríguez A, Sierra Madero J. Mexican perspective on the Mosaico HIV vaccine trial. Lancet HIV 2023; 10:e426-e427. [PMID: 37216956 DOI: 10.1016/s2352-3018(23)00114-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2023] [Accepted: 05/05/2023] [Indexed: 05/24/2023]
Affiliation(s)
- Brenda Crabtree Ramírez
- Departamento de Infectología, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico
| | | | - Carlos Cabrera
- Unidad de Atención Médica e Investigación en Salud, Mérida, Yucatán, Mexico
| | - Carlos Del Río
- Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA
| | | | - Juan Sierra Madero
- Departamento de Infectología, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico.
| |
Collapse
|
4
|
Naghdi R, Nguyen G, Vazquez CM, Antonio CM, Cabrera C, Chandra A, Chok J. Assessing Health Care Professionals' Mindset in Adopting Telemedicine Post COVID-19: Pilot Questionnaire Study. JMIR Form Res 2023; 7:e44806. [PMID: 37266997 DOI: 10.2196/44806] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2022] [Revised: 04/26/2023] [Accepted: 04/27/2023] [Indexed: 06/03/2023] Open
Abstract
BACKGROUND Amidst the COVID-19 pandemic, the traditional health care model has evolved toward a more patient-centric model. In relation to this trend, digital health services have seen an acceleration, which may have significant implications for the health care model. Due to the impact of COVID-19 on health care facilities, it is important to explore health professionals' willingness to adopt a patient-centric digital health delivery model for medicine and health care. OBJECTIVE The aim of this study was to pilot a survey that assesses the impact and implementation of telehealth in view of health care providers prior to and post COVID-19. METHODS A total of 26 volunteer health care professionals participated in the pilot study, of which 19/26 (73%) completed the general demographics portion. Among these respondents, 9/26 (35%) completed the entirety of the survey. The questionnaire included questions relating to general demographics, accessibility and benefits, usability, and engagements with telemedicine. Participants were randomly assigned to 1 of the 4 questionnaire designs (A-D) based on their expertise in telehealth. Of the 9 total participants who completed their randomly assigned questionnaire, 1 (11%) was randomly assigned to A, 3 (33%) were randomly assigned to B, 2 (22%) were randomly assigned to C, and 3 (33%) were randomly assigned to D. RESULTS Responses and data from the study questionnaire were collected from Qualtrics. Microsoft Excel was used for data organization. Due to limited responses and data, no advanced statistical software was implemented. From the 9 participants who completed the entirety of the survey, responses from those with telehealth experience (n=4) showed that telehealth was preferred for follow-ups, lab results, and consultations, and that with telehealth, there was greater flexibility with appointment times and a decrease in the number of patients seen. Among the 4 health care providers with telehealth experience, all of them believed it improved accessibility and reduced physical barriers; health care professionals believed telehealth reduced translational barriers with patients. Among health care professionals without telehealth experience (n=5), 60% (3/5) reported a decrease in appointments for in-office visits post COVID-19 and strongly agreed or agreed that telehealth could influence the quality of care for patients. All 5 participants also reported no general concerns about telehealth prior to the pandemic and agreed that it would provide accessibility for patients. CONCLUSIONS Preliminary findings of our pilot study showed initial support of a dynamical shift within the health care model due to the rise in the use of telehealth services between health care providers and patients but no statistically significant results. Further research and investigation with a larger sample size is warranted to better understand the mindset of health care professionals in adopting telemedicine post COVID-19.
Collapse
Affiliation(s)
- Rozhin Naghdi
- Keck Graduate Institute, Claremont, CA, United States
| | - Gianhu Nguyen
- Keck Graduate Institute, Claremont, CA, United States
| | | | | | | | | | - Jay Chok
- Keck Graduate Institute, Claremont, CA, United States
| |
Collapse
|
5
|
Simard MA, Geist F, Cabrera C, Viteri S, Albers J, Zuehlsdorf M, Karachaliou N. Abstract 6776: Spatial transcriptomics of response to tepotinib treatment in a patient with NSCLC. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-6776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
Background: While cancer therapies are becoming increasingly more targeted, our understanding of the genomic changes occurring during these treatments is lacking. Moreover, the tumoral heterogeneity and its spatial distribution remain important obstacles in predicting tumor evolution and treatment responses. In recent years, genomic spatial profiling techniques have shed light on this complexity by detecting gene expression changes in heterogenous tumor regions and their microenvironment over the course of treatment.
Methods: Tepotinib is a highly selective and potent MET class Ib inhibitor, approved for the treatment of patients with NSCLC with MET exon 14 skipping alterations. To detect genomic changes during neoadjuvant treatment with tepotinib, a GeoMx® digital spatial profiler (DSP; Nanostring Technologies) analysis was conducted in paired baseline and on-treatment patient samples. GeoMx® DSP was performed by selecting regions of interest with nuclear, TTF-1, CD3 and CD33 morphology markers followed by next-generation sequencing (NGS) using the Cancer Transcriptome Atlas RNA panel (>1,800 cancer-related genes).
Results: Following a poor response to chemotherapy, neoadjuvant tepotinib treatment was initiated in a 54-year-old female, never-smoker with NSCLC harboring a MET exon 14 alteration. Owing to a good response to tepotinib, surgical resection of the tumor was decided by the tumor board given the downgrading (from IIIB to IA1) and resulting in a major pathological response. This resection allowed spatial transcriptomics to be compared to a baseline biopsy from the same patient. MET signaling inhibition by tepotinib treatment increased immune cell infiltration in the tumor microenvironment compared to the baseline sample. This enhanced tumoral immune cell density was shown by the fluorescent morphology markers and confirmed through spatial deconvolution of the NGS results. It was further characterized by the significantly altered gene expression levels between the two samples. Gene ontology (GO) assessment of the differentially expressed genes revealed GO terms associated with tumorigenesis in the basal sample, such as cell mobility and motility, vascular epithelial growth factor production and cell communication. In turn, the tepotinib-treated tissue mainly exhibited tumor-clearing characteristics, including antigen processing and presentation through major histocompatibility complex classes I & II, T cell-mediated toxicity, and granulocyte and leukocyte activation.
Conclusion: This is the first spatial genomic characterization of the effect of tepotinib on the tumor and its microenvironment in a patient with NSCLC over time. Results from this case report highlight the impact of MET inhibition by tepotinib on the tumor immune microenvironment, likely enabling the recruitment of antigen-presenting cells for tumor clearance, while reducing the expression of tumor-promoting genes.
Citation Format: Manon A. Simard, Felix Geist, Carlos Cabrera, Santiago Viteri, Joachim Albers, Michael Zuehlsdorf, Niki Karachaliou. Spatial transcriptomics of response to tepotinib treatment in a patient with NSCLC. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6776.
Collapse
Affiliation(s)
| | - Felix Geist
- 1Research Unit Oncology, Merck KGaA, Darmstadt, Germany
| | | | | | | | | | | |
Collapse
|
6
|
Cabrera C, Frisk C, Löfström U, Lyngå P, Linde C, Hage C, Persson H, Eriksson MJ, Wallén H, Persson B, Ekström M. Relationship between iron deficiency and expression of genes involved in iron metabolism in human myocardium and skeletal muscle. Int J Cardiol 2023; 379:82-88. [PMID: 36931398 DOI: 10.1016/j.ijcard.2023.03.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/23/2023] [Accepted: 03/13/2023] [Indexed: 03/19/2023]
Abstract
BACKGROUND Iron deficiency (ID) is associated with adverse prognosis in patients with heart failure. This study aims to investigate the relationship between ID and expression of genes involved in iron metabolism in human myocardium and skeletal muscle, focusing on Transferrin 1 receptor (TfR1), the main pathway of cellular iron uptake. METHODS Patients undergoing elective CABG were assessed prior to surgery with echocardiography and serum iron parameters. Core needle biopsies were collected from the left and right ventricle (LV, RV), the right atrium and intercostal skeletal muscle (SM). Gene expression analyses were done by mRNA sequencing. RESULTS Of 69 patients (median age 69 years, 91% men), 28% had ID. 26% had HFrEF, 25% had HFpEF physiology according to echocardiographic findings and NT-proBNP levels, and 49% had normal LV function. The expression of TfR1 was increased in patients with ID compared to patients without ID in ventricular tissue (p = 0.04) and in intercostal SM (p = 0.01). The increase in TfR1 expression in LV and RV was more pronounced when analysing patients with absolute ID (S-Ferritin<100 μg/L). Analysing the correlation between various iron parameters, S-Ferritin levels showed the strongest correlation with TfR1 expression. There was no correlation with NT-proBNP levels and no difference in TfR1 expression between different HF phenotypes. CONCLUSIONS In patients undergoing elective CABG we found an association between ID and increased TfR1 expression in myocardium regardless of LV function, indicating physiologically upregulated TfR1 expression in the presence of ID to restore intracellular iron needs. CLINICAL TRIAL REGISTRATION Clinicaltrials.govNCT03671122.
Collapse
Affiliation(s)
- C Cabrera
- Karolinska Institutet, Dept. of Clinical Science and Education, Södersjukhuset, Stockholm, Sweden..
| | - C Frisk
- Uppsala University, Dept. of Cell and Molecular Biology, Science for Life Laboratory, Uppsala, Sweden
| | - U Löfström
- Karolinska Institutet, Dept. of Medicine, Stockholm, Sweden
| | - P Lyngå
- Karolinska Institutet, Dept. of Clinical Science and Education, Södersjukhuset, Stockholm, Sweden
| | - C Linde
- Karolinska Institutet, Dept. of Medicine, Stockholm, Sweden
| | - C Hage
- Karolinska Institutet, Dept. of Medicine, Stockholm, Sweden
| | - H Persson
- Karolinska Institutet, Division of Cardiovascular Medicine, Dep. of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden
| | - M J Eriksson
- Karolinska Institutet, Dept. of Molecular Medicine and Surgery
| | - H Wallén
- Karolinska Institutet, Division of Cardiovascular Medicine, Dep. of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden
| | - B Persson
- Uppsala University, Dept. of Cell and Molecular Biology, Science for Life Laboratory, Uppsala, Sweden
| | - M Ekström
- Karolinska Institutet, Division of Cardiovascular Medicine, Dep. of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden
| |
Collapse
|
7
|
Garzón Ibañez M, Aguado Esteban C, García-Peláez B, Gimenez Capitán A, Vives Usano M, Berrocal L, Valarezo J, Aguilar A, Garcia Casabal F, Viteri Ramirez S, Cabrera C, Gonzalez Cao M, Rosell R, Molina-Vila M, de las Casas C. EP08.02-032 High Efficiency Multiplex Detection of Molecular Alterations in Supernatants of Pleural Effusion and Cerebrospinal Fluid. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
8
|
Capitán AMG, Rubisntein P, Aguilar-Hernández A, González-cao M, Moya I, Viteri S, Cabrera C, Ramón y Cajal S, Loor K, Culebras M, Sansano I, Rubisntein F, Valarezo J, Mayo-de las-Casas C, Pedraz C, Beechem J, Warren S, Rosell R, Molina-Vila MÁ. Abstract 1424: Prospective validation of a mRNA signature in plasma for the diagnosis of early stage lung cancer. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-1424] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Non-small cell lung cancer (NSCLC) is usually diagnosed at stages IIIB-IV, with a median overall survival that does not exceed two years. In contrast, patients diagnosed at early and locally advanced stages (I-IIIA) can undergo surgery and have a significantly better prognosis. Imaging technologies often detect lung nodules of unknown significance that pose a diagnostic challenge. In a proof-of-concept study, based on a 76-patient cohort, we developed a preliminary mRNA expression signature in plasma that discriminated healthy individuals from early-stage NSCLC patients with AUC=0.98. Here, we aimed to expand the training cohort, to refine the diagnostic signature and to prospectively validate the final signature in the clinical setting.
Methods: Two hundred and thirty individuals with pulmonary nodules suspicious of lung cancer have been enrolled in the training cohort. All of them underwent bronchoscopy, fine needle aspiration, percutaneous or surgical biopsy to confirm the diagnosis. Circulating-free RNA (cfRNA) has been isolated from plasma using an automatic extraction method (Qiasymphony, Qiagen). Purified cfRNA has been quantified using Qubit®, retrotranscribed and pre-amplified with 14 cycles using the Low RNA Input Amplification kit (NanoString Technologies). Gene expression analysis has been performed on the nCounter platform using the PanCancer IO360࣪ panel (NanoString Technologies), which can detect 770 transcripts related to tumor biology, micro-environment and the immune system.
Results: One hundred twenty-six patients have been analyzed so far; plasma samples have been successfully analyzed by nCounter in all cases. Ongoing analysis reveal differential patterns of gene expression in early-stage NSCLC patients versus non-cancer individuals. Using a bioinformatics recursive feature elimination algorithm, we have selected a diagnostic signature with an area under the ROC curve of 0.89. The signature scores derived from the algorithm are significantly different between the non-cancer and NSCLC cases. Final results of the training and validation cohort will be presented at the meeting
Conclusions: Plasma RNA expression signatures can be a useful tool to guide clinical decision in patients with pulmonary nodules suspicious of malignancy, orienting towards surgery or observation.
Citation Format: Ana María Giménez Capitán, Pablo Rubisntein, Andrés Aguilar-Hernández, María González-cao, Irene Moya, Santiago Viteri, Carlos Cabrera, Santiago Ramón y Cajal, Karina Loor, Mario Culebras, Irene Sansano, Federico Rubisntein, Joselyn Valarezo, Clara Mayo-de las-Casas, Carlos Pedraz, Joseph Beechem, Sarah Warren, Rafael Rosell, Miguel Ángel Molina-Vila. Prospective validation of a mRNA signature in plasma for the diagnosis of early stage lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1424.
Collapse
Affiliation(s)
| | | | | | - María González-cao
- 4Instituto Oncológico Dr Rosell (IOR) Quirón-Dexeus Hospital, Barcelona, Spain
| | - Irene Moya
- 5Instituto Oncológico Dr. Rosell (IOR), Hospital General de Cataluña, Sant Cugat, Spain
| | | | | | - Santiago Ramón y Cajal
- 7Servicio de Anatomía Patológica, Hospital Universitario Vall d'hebron, Universidad Autónoma de Barcelona, Barcelona, Spain
| | - Karina Loor
- 8Servicio de Nrumología, Departamento de Medicina, Hospital Universitario Vall d'hebron, Universidad Autónoma de Barcelona, Barcelona, Spain
| | - Mario Culebras
- 8Servicio de Nrumología, Departamento de Medicina, Hospital Universitario Vall d'hebron, Universidad Autónoma de Barcelona, Barcelona, Spain
| | - Irene Sansano
- 9Servicio de Anatomía Patológica,Hospital Universitario Vall d'hebron, Universidad Autónoma de Barcelona, Barcelona, Spain
| | | | | | | | | | | | | | - Rafael Rosell
- 11Catalan Institute of Oncology and Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol. Instituto Oncológico Dr. Rosell (IOR), Quirón-Dexeus University Hospital, Barcelona, Spain
| | | |
Collapse
|
9
|
Aguado CA, Garcia B, Aguilar-Hernández A, Martínez-Bueno A, Vives-Usano M, Garcia-Casabal F, Román R, Meshoulam E, Aldeguer E, Jordana-Ariza N, García-Mosquera JJ, Cabrera C, Viteri S, Rodríguez S, Berrocal-Gómez L, Rubinstein P, Mayo-de-las-Casas C, Rosell R, Molina-Vila MÁ. Abstract 1610: Primary cultures from malignant pleural effusions and ascites for drug screening in personalized therapy. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-1610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: A significant percentage of patients (p.) with solid tumors present with pleural effusion or ascitic fluid during disease history. Although isolation of viable malignant cells from these fluids for drug screening and other experimental purposes have been described in the literature, the success rate in obtaining pure cultures is low and the technique is rarely employed in the clinical setting. Here, we present the results of the implementation in our hospital of routine primary culture and subsequent drug testing from pleural effusions and ascites.
Methods: 22 pleural effusions (PE) and 11 ascitic fluid from 33 p. were collected; three colon, one esophagous, one melanoma, eight ovarian, one pancreatic and 19 lung cancer. Total cells were isolated by centrifugation, erythrocytes discarded by density gradient and the remaining cells cultured in RPMI + 20%FBS. Primary cultures were genotyped by next generation sequencing (NGS), FISH, qPCR and nCounter. The antitumor effects of several drugs were tested by MTT, including tyrosine kinase, PARP and KRAS inhibitors and chemotherapeutic agents such as cis-platinum or pemetrexed.
Results: Primary cultures were attempted from 33 malignant pleural effusions and ascites samples. Cells grew ≥3 passages and were genotyped in 28/33 cases (84%). Eleven primary cultures were pan-negative by NGS, suggesting that they derived either from non-tumor cells or from a minor sub-clone within the tumor. In contrast, 17 primary cultures showed alterations in oncogenes or tumor supressor genes, allelic fractions were ≥70% in 11 cases. Synchronous liquid biopsies or FFPE biopsies were available for the 17 primary cultures; the same genetic alterations were present in all cases. Five primary cultures with drivers at ≥70% allelic fraction (KRAS G12C; ALK and ROS1 fusions; MET and FGFR1 amplifications) were used for MTT assays. In the three cases where the patient was administered the same drugs tested in primary cultures, results were concordant.
Conclusions: Primary culture of pleural effusions and ascites can be implemented in the clinical setting with a significant success rate. Drug testing in primary cultures can be of help in treatment selection.
Citation Format: Cristina A. Aguado, Beatriz Garcia, Andrés Aguilar-Hernández, Alejandro Martínez-Bueno, Marta Vives-Usano, Florencia Garcia-Casabal, Ruth Román, Ekaterina Meshoulam, Erika Aldeguer, Nuria Jordana-Ariza, Juan José García-Mosquera, Carlos Cabrera, Santiago Viteri, Sonia Rodríguez, Laura Berrocal-Gómez, Pablo Rubinstein, Clara Mayo-de-las-Casas, Rafael Rosell, Miguel Ángel Molina-Vila. Primary cultures from malignant pleural effusions and ascites for drug screening in personalized therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1610.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Ekaterina Meshoulam
- 3Instituto Oncológico Dr. Rosell, Centro Médico Teknon, Quirónsalud, Barcelona, Spain
| | | | | | | | - Carlos Cabrera
- 4UOMI Cancer Center, Clínica Mi Tres Torres, Barcelona, Spain
| | - Santiago Viteri
- 4UOMI Cancer Center, Clínica Mi Tres Torres, Barcelona, Spain
| | | | | | | | | | - Rafael Rosell
- 6Catalan Institute of Oncology and Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona; cInstituto Oncológico Dr. Rosell (IOR), Quirón-Dexeus University Hospital, Barcelona, Spain
| | | |
Collapse
|
10
|
Ezponda A, Casanova C, Divo M, Marín-Oto M, Cabrera C, Marín JM, Bastarrika G, Pinto-Plata V, Martin-Palmero Á, Polverino F, Celli BR, de Torres JP. Chest CT-assessed comorbidities and all-cause mortality risk in COPD patients in the BODE cohort. Respirology 2022; 27:286-293. [PMID: 35132732 PMCID: PMC9303420 DOI: 10.1111/resp.14223] [Citation(s) in RCA: 17] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2021] [Revised: 01/11/2022] [Accepted: 01/19/2022] [Indexed: 12/16/2022]
Abstract
BACKGROUND AND OBJECTIVE The availability of chest computed tomography (CT) imaging can help diagnose comorbidities associated with chronic obstructive pulmonary disease (COPD). Their systematic identification and relationship with all-cause mortality have not been explored. Furthermore, whether their CT-detected prevalence differs from clinical diagnosis is unknown. METHODS The prevalence of 10 CT-assessed comorbidities was retrospectively determined at baseline in 379 patients (71% men) with mild to severe COPD attending pulmonary clinics. Anthropometrics, smoking history, dyspnoea, lung function, exercise capacity, BODE (BMI, Obstruction, Dyspnoea and Exercise capacity) index and exacerbations rate were recorded. The prevalence of CT-determined comorbidities was compared with that recorded clinically. Over a median of 78 months of observation, the independent association with all-cause mortality was analysed. A 'CT-comorbidome' graphically expressed the strength of their association with mortality risk. RESULTS Coronary artery calcification, emphysema and bronchiectasis were the most prevalent comorbidities (79.8%, 62.7% and 33.9%, respectively). All were underdiagnosed before CT. Coronary artery calcium (hazard ratio [HR] 2.09; 95% CI 1.03-4.26, p = 0.042), bronchiectasis (HR 2.12; 95% CI 1.05-4.26, p = 0.036) and low psoas muscle density (HR 2.61; 95% CI 1.23-5.57, p = 0.010) were independently associated with all-cause mortality and helped define the 'CT-comorbidome'. CONCLUSION This study of COPD patients shows that systematic detection of 10 CT-diagnosed comorbidities, most of which were not detected clinically, provides information of potential use to patients and clinicians caring for them.
Collapse
Affiliation(s)
- Ana Ezponda
- Radiology Department, Clínica Universidad de Navarra, Pamplona, Spain
| | - Ciro Casanova
- Pulmonary Department, Hospital Ntra Sra de Candelaria, Tenerife, Spain.,Respiratory Research Unit, Hospital Ntra Sra de Candelaria, Tenerife, Spain
| | - Miguel Divo
- Pulmonary Department, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Marta Marín-Oto
- Pulmonary Department, Clínica Universidad de Navarra, Pamplona, Spain
| | - Carlos Cabrera
- Pulmonary Department, Hospital Universitario Doctor Negrín, Las Palmas, Spain
| | - Jose M Marín
- Pulmonary Department, Hospital Universitario Miguel Servet, Instituto Aragonés Ciencias Salud & CIBERES, Zaragoza, Spain
| | - Gorka Bastarrika
- Radiology Department, Clínica Universidad de Navarra, Pamplona, Spain
| | - Víctor Pinto-Plata
- Pulmonary Department, Baystate Medical Center, Springfield, Massachusetts, USA
| | | | - Francesca Polverino
- Asthma and Airway Disease Research Center, University of Arizona, Tucson, Arizona, USA
| | - Bartolome R Celli
- Pulmonary Department, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Juan P de Torres
- Pulmonary Department, Clínica Universidad de Navarra, Pamplona, Spain.,Respiratory Investigation Unit, Queen's University, Kingston, Ontario, Canada.,Respirology and Sleep Medicine Division, Queen's University, Kingston, Ontario, Canada
| |
Collapse
|
11
|
Lopera M, Vera R, Tapia C, Cabrera C, Gonzales-Zamora J, Alave J. 583. SARS-CoV-2 Spike Protein S1/S2 Antibodies after Vaccination with Sinopharm in Peruvian Physicians. Open Forum Infect Dis 2021. [PMCID: PMC8644935 DOI: 10.1093/ofid/ofab466.781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Peru started its national vaccination campaign in February 2021 using Sinopharm vaccine, targeting healthcare personnel on its initial phase. Although the immunogenicity of this vaccine was tested in clinical trials, there are no studies that evaluated the humoral response post vaccination in Peru.
Methods
We conducted a cross sectional study, which objective was to evaluate the humoral immunogenicity triggered by the Sinopharm vaccine in Peruvian physicians. We collected demographic and epidemiologic data via an electronic. The SARS-CoV-2 spike protein S1/S2 antibodies were measured by chemiluminescense (Liaison®). A positive test was defined as >15 U/ml, which has correlation of 95% with neutralizing antibodies measured by plaque reduction neutralizing test.
Results
92 participants were enrolled in the study. The epidemiologic characteristics are described in table 1. The mean level of antibodies measured at least 2 weeks from the second vaccine dose was 67.5 ± 70.5 U/ml. 85.7% of the study cohort had positive S1/S2 antibodies. In the univariate analysis, an imperfect negative correlation was found between the level of antibodies and participants’ age (r= -0.24; regression F test 5.25; p = 0.0242). A weak negative correlation was observed between the antibody titer and the time elapsed from the second vaccine dose and the day of antibody measurement (r= -0.17). A higher antibody level post vaccine was found in individuals who worked in COVID units (105.5 U / mL vs 58.2 U / mL; p = 0.0125), and in participants with history of COVID (216.5 U / mL vs 81.2 U / mL; p = < 0.0000). Hypertension was associated with lower antibody titers (36.9 U / mL vs. 74.6; p = 0.0464). In the multivariate analysis, working in COVID units, having previous COVID infection and shorter time from second vaccine dose and day of antibody measurement were associated with higher antibody levels post vaccine (table 2).
Conclusion
Our study showed that the time elapsed from the second vaccine dose and the day of antibody measurement, having previous COVID-19 infection and working in COVID -19 units may help to predict higher antibody titers post vaccine. Larger studies to evaluate the humoral response post Sinopharm vaccine and its clinical implications are still needed in Peru.
Disclosures
All Authors: No reported disclosures
Collapse
Affiliation(s)
- Maria Lopera
- Centro Nacional Salud Renal - Essalud, Lima, Lima, Peru
| | - Romina Vera
- Centro Nacional Salud Renal - Essalud, Lima, Lima, Peru
| | - Carlos Tapia
- Centro Nacional Salud Renal - Essalud, Lima, Lima, Peru
| | - Carlos Cabrera
- Hospital Nacional Carlos Alberto Seguin Escobedo - Essalud, Arequipa, Arequipa, Peru
| | | | | |
Collapse
|
12
|
García Peláez B, Gimenez-Capitán A, Vives Usano M, Roman R, Garzón Ibañez M, Aguado Esteban C, Rodríguez S, Aldeguer E, Jordana Ariza N, Viteri S, Aguilar-Hernández A, Moya I, Cabrera C, Catalán M, Gonzalez-Cao M, García Román S, Bertrán- Alamillo J, Garcia-Casabal F, Rosell R, Molina M, Mayo-De-Las-Casas C. P59.03 Comparison of Two RNA-Based Platforms for Detection of Fusions and Met Splicing Variant in Non Small Cell Lung Cancer Samples. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.592] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
13
|
Aguado Esteban C, García Peláez B, Cabrera C, Viteri S, Aguilar-Hernández A, Rodríguez S, Aldeguer E, Berrocal L, Roman R, Rubenstein P, Garcia-Casabal F, Mayo-De-Las-Casas C, Rosell R, Molina-Vila M. P68.05 Human Lung Carcinoma Primary Cultures From Malignant Pleural Effusions as a Tool for Drug Screening and Personalized Therapy. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.692] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
14
|
Ezponda A, Casanova C, Cabrera C, Martin-Palmero Á, Marin-Oto M, Marín JM, Pinto-Plata V, Divo M, Celli BR, Zulueta JJ, Bastarrika G, de-Torres JP. Psoas Muscle Density Evaluated by Chest CT and Long-Term Mortality in COPD Patients. Arch Bronconeumol 2021; 57:533-539. [PMID: 35699031 DOI: 10.1016/j.arbr.2021.04.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2020] [Accepted: 04/08/2021] [Indexed: 06/15/2023]
Abstract
RATIONALE Poor muscle quality in COPD patients relates to exercise intolerance and mortality. Muscle quality can be estimated on computed tomography (CT) by estimating psoas density (PsD). We tested the hypothesis that PsD is lower in COPD patients than in controls and relates to all-cause mortality. METHODS At baseline, PsD was measured using axial low-dose chest CT images in 220 COPD patients, 80% men, who were 65±8 years old with mild to severe airflow limitation and in a control group of 58 subjects matched by age, sex, body mass index (BMI) and body surface area (BSA). COPD patients were prospectively followed for 76.5 (48-119) months. Anthropometrics, smoking history, BMI, dyspnoea, lung function, exercise capacity, BODE index and exacerbations history were recorded. Cox proportional risk analysis determined the factors more strongly associated with long-term mortality. RESULTS PsD was lower in COPD patients than in controls (40.5 vs 42.5, p=0.045). During the follow-up, 54 (24.5%) deaths occurred in the COPD group. PsD as well as age, sex, pack-year history, FEV1%, 6MWD, mMRC, BODE index, were independently associated with mortality. Multivariate analysis showed that age (HR 1.06; 95% CI 1.02-1.12, p=0.006) and CT-assessed PsD (HR 0.97; 95%CI 0.94-0.99, p=0.023) were the variables independently associated with all-cause mortality. CONCLUSIONS In COPD patients with mild to severe airflow limitation, chest CT-assessed psoas muscle density was lower than in matched controls and independently associated with long-term mortality. Muscle quality using the easy to evaluate psoas muscle density from chest CT may provide clinicians with important prognostic information in COPD.
Collapse
Affiliation(s)
- Ana Ezponda
- Radiology Department, Clínica Universidad de Navarra, Pamplona, Spain
| | - Ciro Casanova
- Pulmonary Department, Hospital Ntra Sra de Candelaria, Tenerife, Spain; Respiratory Research Unit, Hospital Ntra Sra de Candelaria, Tenerife, Spain
| | - Carlos Cabrera
- Pulmonary Department, Hospital Universitario Doctor Negrín, Las Palmas, Spain
| | | | - Marta Marin-Oto
- Pulmonary Department, Clínica Universidad de Navarra, Pamplona, Spain
| | - Jose M Marín
- Pulmonary Department, Hospital Universitario Miguel Servet, Instituto Aragonés Ciencias Salud & CIBERES, Zaragoza, Spain
| | | | - Miguel Divo
- Pulmonary Department, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Bartolome R Celli
- Pulmonary Department, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Javier J Zulueta
- Pulmonary Department, Clínica Universidad de Navarra, Pamplona, Spain
| | - Gorka Bastarrika
- Radiology Department, Clínica Universidad de Navarra, Pamplona, Spain
| | - Juan P de-Torres
- Respirology and Sleep Division, Queen's University, Kingston, Canada; Pulmonary Department, Clínica Universidad de Navarra, Pamplona, Spain.
| |
Collapse
|
15
|
Ibañez MG, Gimenez-Capitán A, Usano MV, Lladó RR, Rodriguez S, Aldeguer E, Pelaez BG, Ariza NJ, Aguado C, Viteri S, Aguilar A, Moya I, Cabrera C, Catalán MJ, cao MG, Garcia-Roman S, Alamillo JB, Casabal FG, Rosell R, Molina-Vila MA, De Las Casas CDLCM. Abstract 290: Comparison of clinically relevant fusions detection using two multiplexing RNA based platforms: nCounter and GeneReader. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Fusions involving the tyrosine kinase receptor genes ALK, ROS1, RET, NTRK or MET exon 14 skipping variant (METex14) are present in a significant percentage of advanced solid tumors and their accurate identification is critical to guide targeted therapies. While FISH has traditionally been considered the gold standard for fusion analysis, it is costly and shows biases. GeneReader Next Generation Sequencing (NGS) (Qiagen) and nCounter (Nanostring) are two technologies allowing simultaneous detection of fusion transcripts and splicing variants. In this work we compared the performance of both platforms for fusion and splicing variant detection in advanced solid tumor patients.
Methods: RNAs from 40 selected solid tumors were purified using High Pure FFPET RNA Isolation Kit (Hoffman-La Roche) and prospectively analyzed by GeneReader and nCounter. The custom nCounter codeset used targets fusions involving ALK, ROS1, RET, NTRK1-3, NRG1 and MET exon 14 skipping variant based on a dual strategy: detection of specific fusion transcripts and imbalances between the 3' and 5' mRNA regions, enabling the recognition of even those fusions not identified with the specific primers. Reporter counts from nCounter were collected with the nSolver Analysis software (Nanostring) and analyzed using an algorithm developed in the laboratory. The design of QIAact Lung Fusion Custom GeneReader panel contains specific junction probes for the detection of fusions in ALK, ROS1, RET, FGFR1- 3, NRG1, NTRK1- 3, EGFR, BRAF, and MET exon 14 skipping variant. GeneReader analysis and interpretation were performed with the QCI-Analyze and QCI-Interpret software's (Qiagen).
Results: Valid results were obtained for 40/40 (100%) of samples tested. Paired analysis showed a 97.5% concordance (39/40 cases) between the results obtained by nCounter and GeneReader NGS, corresponding to a Cohen's kappa of 0.935 [CI=0.809-1.0]. Overall, 8 samples tested positive for fusion transcripts, namely EML4-ALK (n=4), CCDC6-RET (n=1), KIF5B-RET (n=1), EZR-ROS1 (n=1) and ETV6-NTRK3 (n=1). In addition, MET exon 14 skipping variant was detected in two samples. The discordant case between nCounter and NGS corresponded to a rare RET fusion only detected by 3'-5' imbalance using nCounter, while the remaining 29 patients were pan-negative. In one of them, an uncommon HLA-DRB1-MET fusion not included in the nCounter codeset, was found by the GeneReader custom panel.
Conclusions: RNA-based NGS and nCounter show excellent concordance for detection of gene fusions and MET splicing variant in advanced solid tumors.
Citation Format: Mónica Garzón Ibañez, Ana Gimenez-Capitán, Marta Vives Usano, Ruth Román Lladó, Sonia Rodriguez, Erika Aldeguer, Beatriz García Pelaez, Nuria Jordana Ariza, Cristina Aguado, Santiago Viteri, Andrés Aguilar, Irene Moya, Carlos Cabrera, Maria Jose Catalán, Maria Gonzalez cao, Silvia Garcia-Roman, Jordi Bertran Alamillo, Florencia Garcia Casabal, Rafael Rosell, Miguel Angel Molina-Vila, Clara De La Caridad Mayo De Las Casas. Comparison of clinically relevant fusions detection using two multiplexing RNA based platforms: nCounter and GeneReader [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 290.
Collapse
Affiliation(s)
| | | | | | | | | | - Erika Aldeguer
- 1Pangaea Oncology. Quiron Dexeus Institut, Barcelona, Spain
| | | | | | | | - Santiago Viteri
- 2Dr. Rosell Oncology Institut. Quiron Dexeus Institut, Barcelona, Spain
| | - Andrés Aguilar
- 2Dr. Rosell Oncology Institut. Quiron Dexeus Institut, Barcelona, Spain
| | - Irene Moya
- 2Dr. Rosell Oncology Institut. Quiron Dexeus Institut, Barcelona, Spain
| | - Carlos Cabrera
- 2Dr. Rosell Oncology Institut. Quiron Dexeus Institut, Barcelona, Spain
| | | | | | | | | | | | - Rafael Rosell
- 2Dr. Rosell Oncology Institut. Quiron Dexeus Institut, Barcelona, Spain
| | | | | |
Collapse
|
16
|
Ithurralde J, Pérez-Clariget R, Saadoun A, Genovese P, Cabrera C, López Y, Feed O, Bielli A. Gestational nutrient restriction under extensive grazing conditions: Effects on muscle characteristics and meat quality in heavy lambs. Meat Sci 2021; 179:108532. [PMID: 33965690 DOI: 10.1016/j.meatsci.2021.108532] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2020] [Revised: 03/22/2021] [Accepted: 04/29/2021] [Indexed: 10/21/2022]
Abstract
We evaluated maternal undernutrition effects induced by a lower natural pasture allowance (gestation days 30-143) on histological-biochemical and meat traits in muscles Semitendinosus, cranial Gluteobiceps and Supraspinatus from 200-day old male and female lambs. Maternal undernutrition increased oxidative and reduced glycolytic fibers in all muscles (P ≤ 0.01). Maternal undernutrition reduced the diameter of glycolytic fibers in the cranial Gluteobiceps of exclusively female lambs (P = 0.05) and reduced the diameter of oxidative fibers in the Supraspinatus of exclusively male lambs (P = 0.02). Maternal undernutrition increased lipid content in the Supraspinatus of females (P = 0.001), reduced lactate content (P = 0.03) and WB shear force (P = 0.02) in the Semitendinosus of females, and increased cooking losses in the Semitendinosus of males (P = 0.0069). In conclusion, gestational nutrient restriction induced fetal programming effects on muscle characteristics of lambs. Moreover, our study demonstrates that maternal undernutrition influences muscle and meat characteristics in a sex and muscle-dependent way.
Collapse
Affiliation(s)
- J Ithurralde
- Departamento de Producción Animal y Pasturas, Facultad de Agronomía, Universidad de la República, Garzón 780, 12900 Montevideo, Uruguay.
| | - R Pérez-Clariget
- Departamento de Producción Animal y Pasturas, Facultad de Agronomía, Universidad de la República, Garzón 780, 12900 Montevideo, Uruguay
| | - A Saadoun
- Departamento de Producción Animal y Pasturas, Facultad de Agronomía, Universidad de la República, Garzón 780, 12900 Montevideo, Uruguay
| | - P Genovese
- Departamento de Morfología y Desarrollo, Facultad de Veterinaria, Universidad de la República, A. Lasplaces 1550, 11600 Montevideo, Uruguay
| | - C Cabrera
- Departamento de Producción Animal y Pasturas, Facultad de Agronomía, Universidad de la República, Garzón 780, 12900 Montevideo, Uruguay
| | - Y López
- Research Station 'Dr Mario A. Cassinoni' (EEMAC) Facultad de Agronomía, Route 3, km 363, Paysandú, Uruguay
| | - O Feed
- Research Station 'Dr Mario A. Cassinoni' (EEMAC) Facultad de Agronomía, Route 3, km 363, Paysandú, Uruguay
| | - A Bielli
- Departamento de Morfología y Desarrollo, Facultad de Veterinaria, Universidad de la República, A. Lasplaces 1550, 11600 Montevideo, Uruguay
| |
Collapse
|
17
|
Ezponda A, Casanova C, Cabrera C, Martin-Palmero Á, Marin-Oto M, Marín JM, Pinto-Plata V, Divo M, Celli BR, Zulueta JJ, Bastarrika G, de-Torres JP. Psoas Muscle Density Evaluated by Chest CT and Long-Term Mortality in COPD Patients. Arch Bronconeumol 2021; 57:S0300-2896(21)00133-2. [PMID: 33994243 DOI: 10.1016/j.arbres.2021.04.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2020] [Revised: 04/01/2021] [Accepted: 04/08/2021] [Indexed: 10/21/2022]
Abstract
RATIONALE Poor muscle quality in COPD patients relates to exercise intolerance and mortality. Muscle quality can be estimated on computed tomography (CT) by estimating psoas density (PsD). We tested the hypothesis that PsD is lower in COPD patients than in controls and relates to all-cause mortality. METHODS At baseline, PsD was measured using axial low-dose chest CT images in 220 COPD patients, 80% men, who were 65±8 years old with mild to severe airflow limitation and in a control group of 58 subjects matched by age, sex, body mass index (BMI) and body surface area (BSA). COPD patients were prospectively followed for 76.5 (48-119) months. Anthropometrics, smoking history, BMI, dyspnoea, lung function, exercise capacity, BODE index and exacerbations history were recorded. Cox proportional risk analysis determined the factors more strongly associated with long-term mortality. RESULTS PsD was lower in COPD patients than in controls (40.5 vs 42.5, p=0.045). During the follow-up, 54 (24.5%) deaths occurred in the COPD group. PsD as well as age, sex, pack-year history, FEV1%, 6MWD, mMRC, BODE index, were independently associated with mortality. Multivariate analysis showed that age (HR 1.06; 95% CI 1.02-1.12, p=0.006) and CT-assessed PsD (HR 0.97; 95%CI 0.94-0.99, p=0.023) were the variables independently associated with all-cause mortality. CONCLUSIONS In COPD patients with mild to severe airflow limitation, chest CT-assessed psoas muscle density was lower than in matched controls and independently associated with long-term mortality. Muscle quality using the easy to evaluate psoas muscle density from chest CT may provide clinicians with important prognostic information in COPD.
Collapse
Affiliation(s)
- Ana Ezponda
- Radiology Department, Clínica Universidad de Navarra, Pamplona, Spain
| | - Ciro Casanova
- Pulmonary Department, Hospital Ntra Sra de Candelaria, Tenerife, Spain; Respiratory Research Unit, Hospital Ntra Sra de Candelaria, Tenerife, Spain
| | - Carlos Cabrera
- Pulmonary Department, Hospital Universitario Doctor Negrín, Las Palmas, Spain
| | | | - Marta Marin-Oto
- Pulmonary Department, Clínica Universidad de Navarra, Pamplona, Spain
| | - Jose M Marín
- Pulmonary Department, Hospital Universitario Miguel Servet, Instituto Aragonés Ciencias Salud & CIBERES, Zaragoza, Spain
| | | | - Miguel Divo
- Pulmonary Department, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Bartolome R Celli
- Pulmonary Department, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Javier J Zulueta
- Pulmonary Department, Clínica Universidad de Navarra, Pamplona, Spain
| | - Gorka Bastarrika
- Radiology Department, Clínica Universidad de Navarra, Pamplona, Spain
| | - Juan P de-Torres
- Respirology and Sleep Division, Queen's University, Kingston, Canada; Pulmonary Department, Clínica Universidad de Navarra, Pamplona, Spain.
| |
Collapse
|
18
|
de-Torres JP, O'Donnell DE, Marín JM, Cabrera C, Casanova C, Marín M, Ezponda A, Cosio BG, Martinez C, Solanes I, Fuster A, Neder JA, Gonzalez-Gutierrez J, Celli BR. Clinical and Prognostic Impact of Low Diffusing Capacity for Carbon Monoxide Values in Patients With Global Initiative for Obstructive Lung Disease I COPD. Chest 2021; 160:872-878. [PMID: 33901498 DOI: 10.1016/j.chest.2021.04.033] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2021] [Revised: 03/01/2021] [Accepted: 04/12/2021] [Indexed: 11/28/2022] Open
Abstract
BACKGROUND The Global Initiative for Obstructive Lung Disease (GOLD) does not promote diffusing capacity for carbon monoxide (Dlco) values in the evaluation of COPD. In GOLD spirometric stage I COPD patients, the clinical and prognostic impact of a low Dlco has not been explored. RESEARCH QUESTION Could a Dlco threshold help define an increased risk of death and a different clinical presentation in these patients? STUDY DESIGN AND METHODS GOLD stage I COPD patients (n = 360) were enrolled and followed over 109 ± 50 months. Age, sex, pack-years' history, BMI, dyspnea, lung function measurements, exercise capacity, BODE index, and history of exacerbations were recorded. A cutoff value for Dlco was identified for all-cause mortality and the clinical and physiological characteristics of patients above and below the threshold compared. Cox regression analysis explored the predictive power of that cutoff value for all-cause mortality. RESULTS A Dlco cutoff value of <60% predicted was associated with all-cause mortality (Dlco ≥ 60%: 9% vs Dlco < 60%: 23%, P = .01). At a same FEV1% predicted and Charlson score, patients with Dlco < 60% had lower BMI, more dyspnea, lower inspiratory capacity (IC)/total lung capacity (TLC) ratio, lower 6-min walk distance (6MWD), and higher BODE. Cox multiple regression analysis confirmed that after adjusting for age, sex, pack-years history, smoking status, and BMI, a Dlco < 60% is associated with all-cause mortality (hazard ratio [HR], 95% CI = 3.37, 1.35-8.39; P = .009) INTERPRETATION: In GOLD I COPD patients, a Dlco < 60% predicted is associated with increased risk of death and worse clinical presentation. What the cause(s) of this association are and whether they can be treated need to be determined.
Collapse
Affiliation(s)
- Juan P de-Torres
- Respirology and Sleep Medicine Division, Queen's University, Kingston, Canada.
| | - Denis E O'Donnell
- Respirology and Sleep Medicine Division, Queen's University, Kingston, Canada
| | - Jose M Marín
- Pulmonary Department, Hospital Universitario Miguel Servet, Instituto Aragonés Ciencias Salud & CIBERES, Zaragoza, Spain
| | - Carlos Cabrera
- Pulmonary Department, Hospital Universitario Doctor Negrín, Las Palmas, Spain
| | - Ciro Casanova
- Pulmonary Department, Hospital Ntra Sra de Candelaria, Tenerife, Spain and Respiratory Research Unit, Hospital Ntra Sra de Candelaria, Tenerife, Spain
| | - Marta Marín
- Pulmonary Department, Clínica Universidad de Navarra, Pamplona, Spain
| | - Ana Ezponda
- Radiology Department, Clínica Universidad de Navarra, Pamplona, Spain
| | - Borja G Cosio
- Hospital Universitario Son Espases, Instituto de Investigación Sanitaria de Baleares (IdISBa), Palma, Mallorca, Spain, and Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), Madrid, España
| | - Cristina Martinez
- Department of Respiratory Medicine, Hospital Central de Asturias, Oviedo, Spain
| | - Ingrid Solanes
- Pulmonary Department, Hospital Santa Creu i Sant Pau, Universidad Autónoma de Barcelona, Barcelona, Spain
| | - Antonia Fuster
- Pulmonary Department, Hospital Universitario Son Llatzer, Palma de Mallorca, Spain
| | - J Alberto Neder
- Respirology and Sleep Medicine Division, Queen's University, Kingston, Canada
| | | | | |
Collapse
|
19
|
GARCIA SANCHEZ J, Retat L, Webber L, Cabrera C, Grandy S, Rao N, Bhatt P, Parackal A, Wong D, Wish J, Tangri N. POS-320 INSIDE ANEMIA OF CKD: QUANTIFYING THE EPIDEMIOLOGICAL BURDEN OF ANEMIA OF CKD IN CANADA VIA MICROSIMULATION MODELLING. Kidney Int Rep 2021. [DOI: 10.1016/j.ekir.2021.03.336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
20
|
GARCIA SANCHEZ J, Tangri N, Abdul Sultan A, Batista M, Cabrera C, Chadban S, Chertow G, Kanda E, Li G, Nolan S, Retat L, Xin S, Webber L, Wish J, Xu M. POS-322 INSIDE CKD: PROJECTING THE FUTURE BURDEN OF CHRONIC KIDNEY DISEASE IN THE AMERICAS AND THE ASIA-PACIFIC REGION USING MICROSIMULATION MODELLING. Kidney Int Rep 2021. [DOI: 10.1016/j.ekir.2021.03.338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
21
|
Aguado C, Teixido C, Román R, Reyes R, Giménez-Capitán A, Marin E, Cabrera C, Viñolas N, Castillo S, Muñoz S, Arcocha A, López-Vilaró L, Sullivan I, Aldeguer E, Rodríguez S, Moya I, Viteri S, Cardona AF, Palmero R, Sainz C, Mesa-Guzmán M, Lozano MD, Aguilar-Hernández A, Martínez-Bueno A, González-Cao M, Gonzalvo E, Leenders WPJ, Rosell R, Montuenga LM, Prat A, Molina-Vila MA, Reguart N. Multiplex RNA-based detection of clinically relevant MET alterations in advanced non-small cell lung cancer. Mol Oncol 2020; 15:350-363. [PMID: 33236532 PMCID: PMC7858100 DOI: 10.1002/1878-0261.12861] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2020] [Revised: 10/23/2020] [Accepted: 11/20/2020] [Indexed: 12/13/2022] Open
Abstract
MET inhibitors have shown activity in non‐small‐cell lung cancer patients (NSCLC) with MET amplification and exon 14 skipping (METΔex14). However, patient stratification is imperfect, and thus, response rates have varied widely. Here, we studied MET alterations in 474 advanced NSCLC patients by nCounter, an RNA‐based technique, together with next‐generation sequencing (NGS), fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), and reverse transcriptase polymerase chain reaction (RT–PCR), exploring correlation with clinical benefit. Of the 474 samples analyzed, 422 (89%) yielded valid results by nCounter, which identified 13 patients (3%) with METΔex14 and 15 patients (3.5%) with very‐high MET mRNA expression. These two subgroups were mutually exclusive, displayed distinct phenotypes and did not generally coexist with other drivers. For METΔex14, 3/8 (37.5%) samples positive by nCounter tested negative by NGS. Regarding patients with very‐high MET mRNA, 92% had MET amplification by FISH and/or NGS. However, FISH failed to identify three patients (30%) with very‐high MET RNA expression, among which one received MET tyrosine kinase inhibitor treatment deriving clinical benefit. Our results indicate that quantitative mRNA‐based techniques can improve the selection of patients for MET‐targeted therapies.
Collapse
Affiliation(s)
- Cristina Aguado
- Laboratory of Oncology, Pangaea Oncology, Quirón Dexeus University Hospital, Barcelona, Spain
| | - Cristina Teixido
- Thoracic Oncology Unit, Department of Pathology, Hospital Clínic, Barcelona, Spain.,Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Ruth Román
- Laboratory of Oncology, Pangaea Oncology, Quirón Dexeus University Hospital, Barcelona, Spain
| | - Roxana Reyes
- Thoracic Oncology Unit, Department of Medical Oncology, Hospital Clínic, Barcelona, Spain
| | - Ana Giménez-Capitán
- Laboratory of Oncology, Pangaea Oncology, Quirón Dexeus University Hospital, Barcelona, Spain
| | - Elba Marin
- Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Thoracic Oncology Unit, Department of Medical Oncology, Hospital Clínic, Barcelona, Spain
| | - Carlos Cabrera
- Dr Rosell Oncology Institute, Dexeus University Hospital Quiron Salud Group, Barcelona, Spain
| | - Nuria Viñolas
- Thoracic Oncology Unit, Department of Medical Oncology, Hospital Clínic, Barcelona, Spain
| | - Sergi Castillo
- Division of Medical Oncology, Hospital General de Granollers, Barcelona, Spain
| | - Silvia Muñoz
- Division of Medical Oncology, Hospital General de Granollers, Barcelona, Spain
| | - Ainara Arcocha
- Thoracic Oncology Unit, Department of Medical Oncology, Hospital Clínic, Barcelona, Spain
| | - Laura López-Vilaró
- Department of Pathology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Ivana Sullivan
- Division of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Erika Aldeguer
- Laboratory of Oncology, Pangaea Oncology, Quirón Dexeus University Hospital, Barcelona, Spain
| | - Sonia Rodríguez
- Laboratory of Oncology, Pangaea Oncology, Quirón Dexeus University Hospital, Barcelona, Spain
| | - Irene Moya
- Dr Rosell Oncology Institute, Dexeus University Hospital Quiron Salud Group, Barcelona, Spain
| | - Santiago Viteri
- Dr Rosell Oncology Institute, Dexeus University Hospital Quiron Salud Group, Barcelona, Spain.,Dr Rosell Oncology Institute, Teknon Medical Center, Quiron Salud Group, Barcelona, Spain
| | - Andrés Felipe Cardona
- Foundation for Clinical and Applied Cancer Research-FICMAC, Bogotá, Colombia.,Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia
| | - Ramon Palmero
- Division of Medical Oncology, Catalan Institute of Oncology, L'Hospitalet, Barcelona, Spain
| | - Cristina Sainz
- Center for Applied Medical Research (CIMA), University of Navarra, Spain.,CIBERONC, Madrid, Spain
| | | | - Maria D Lozano
- CIBERONC, Madrid, Spain.,IDISNA, Pamplona, Spain.,Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain
| | | | | | - María González-Cao
- Dr Rosell Oncology Institute, Dexeus University Hospital Quiron Salud Group, Barcelona, Spain
| | - Elena Gonzalvo
- Thoracic Oncology Unit, Department of Pathology, Hospital Clínic, Barcelona, Spain
| | - William P J Leenders
- Department of Biochemistry, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands
| | - Rafael Rosell
- Dr Rosell Oncology Institute, Dexeus University Hospital Quiron Salud Group, Barcelona, Spain.,Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona, Spain.,Universitat Autònoma de Barcelona, Bellaterra, Spain
| | - Luis M Montuenga
- Center for Applied Medical Research (CIMA), University of Navarra, Spain.,CIBERONC, Madrid, Spain.,IDISNA, Pamplona, Spain.,Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain
| | - Aleix Prat
- Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Thoracic Oncology Unit, Department of Medical Oncology, Hospital Clínic, Barcelona, Spain
| | - Miguel A Molina-Vila
- Laboratory of Oncology, Pangaea Oncology, Quirón Dexeus University Hospital, Barcelona, Spain
| | - Noemi Reguart
- Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Thoracic Oncology Unit, Department of Medical Oncology, Hospital Clínic, Barcelona, Spain
| |
Collapse
|
22
|
Pedraz C, Bracht JWP, Filipska M, Aguilar A, García JJ, Cabrera C, Cao MG, Viteri S, Chaib I, Fernández-Bruno M, Rosell R. Abstract 4294: An integrative project for tracing the genes involved in depression and cancer (DeCa) in peripheral blood. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-4294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Adverse psychological reactions may lead to chronic stress, increasing the risk of depression. Altogether, mood disorders reported prior to diagnosis of cancer negatively influence the prognosis. The first evidence that chronic stress is related to cancer was proven in EGFR mutant non-small-cell lung cancer (NSCLC) patients where the release of norepinephrine activates the β-2 adrenergic receptors in the surface of tumor cells, activating signaling pathways that lead to cancer therapy resistance. Through DeCa we will assess the molecular mechanisms that may be involved in both depression and cancer progression. Blood platelet and extracellular vesicle (EV)-derived biomarkers will be analyzed to explore such correlation and find new therapeutic targets.
Methods: Blood from 20 cancer patients was collected at baseline, first evaluation, and upon progression to treatment. Also, patients were asked to fill in the Patient Health Questionnaire 9 to assess depression state at all time points.
Blood was processed within 8 hours and centrifuged for 20 minutes at 120xg at room temperature (RT). The platelet rich-plasma was separated and centrifuged for 20 minutes at 360xg at RT. The miRCURY Exosome Serum/Plasma Kit (Qiagen®) was used to isolate EVs from plasma. Treatment with RNAse A (Sigma-Aldrich®) was performed to remove cell-free RNA prior RNA extraction with TRI Reagent (MRC® Inc). Platelets were resuspended in 30 μl RNAlater (Invitrogen®), and RNA was isolated by miRNeasy Serum/plasma kit (Qiagen®). Total RNA was retrotranscribed, and ADRB2, NLRP3, NGF, TRkB, FAK1, and BDNF expression was assessed by qRT-PCR.
Results: Preliminary results show an overall consistent expression of FAK1 in both EVs and platelets, when compared with the other biomarkers at all time points. Most biomarkers were found more often expressed in EVs than platelets, with a dominance of FAK1 in platelet samples. Initial EV results show a correlation between BDNF and NGF expression in all time points which seem to be connected with treatment outcome. NLRP3 and ADRB2 also seem to be co-expressed in EV samples. Across all genes analyzed, TrKB was not found expressed in EVs nor in platelets. Moreover, NGF was found expressed only in EVs.
Conclusion: DeCa is an ambitious and innovative project that investigates the correlation of two major diseases in order to improve patient outcome and offer a more personalized treatment. In this first phase, we have shown that EVs have different biomarker expression than platelets. Also, results indicate correlation between BDNF-NGF expression in EVs and treatment outcome. Release of these molecules upon stress has been extensively described in literature, so these preliminary results support our hypothesis that molecular changes during acute psychological distress may be implicated in cancer progression. These findings need to be validated in future studies and may pave the way for a dual treatment strategy for both diseases.
Citation Format: Carlos Pedraz, Jillian Wilhelmina Paulina Bracht, Martyna Filipska, Andrés Aguilar, Juan José García, Carlos Cabrera, María González Cao, Santiago Viteri, Imane Chaib, Manuel Fernández-Bruno, Rafael Rosell. An integrative project for tracing the genes involved in depression and cancer (DeCa) in peripheral blood [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 4294.
Collapse
Affiliation(s)
- Carlos Pedraz
- 1Institut d´Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP), Barcelona, Spain
| | | | - Martyna Filipska
- 1Institut d´Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP), Barcelona, Spain
| | - Andrés Aguilar
- 3Instituto Oncológico Dr. Rosell, Quirón Salud Group, Barcelona, Spain
| | - Juan José García
- 3Instituto Oncológico Dr. Rosell, Quirón Salud Group, Barcelona, Spain
| | - Carlos Cabrera
- 3Instituto Oncológico Dr. Rosell, Quirón Salud Group, Barcelona, Spain
| | | | - Santiago Viteri
- 3Instituto Oncológico Dr. Rosell, Quirón Salud Group, Barcelona, Spain
| | - Imane Chaib
- 1Institut d´Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP), Barcelona, Spain
| | | | - Rafael Rosell
- 1Institut d´Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP), Barcelona, Spain
| |
Collapse
|
23
|
Marin E, Teixido C, Carmona-Rocha E, Reyes R, Arcocha A, Viñolas N, Rodríguez-Mues M, Cabrera C, Sánchez M, Vollmer I, Castillo S, Muñoz S, Sullivan IG, Rodriguez A, Garcia M, Alos S, Jares P, Martinez A, Prat A, Molina-Vila MÁ, Reguart N. Usefulness of Two Independent DNA and RNA Tissue-Based Multiplex Assays for the Routine Care of Advanced NSCLC Patients. Cancers (Basel) 2020; 12:E1124. [PMID: 32365867 PMCID: PMC7281583 DOI: 10.3390/cancers12051124] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2020] [Revised: 04/22/2020] [Accepted: 04/23/2020] [Indexed: 02/07/2023] Open
Abstract
Personalized medicine is nowadays a paradigm in lung cancer management, offering important benefits to patients. This study aimed to test the feasibility and utility of embedding two multiplexed genomic platforms as the routine workup of advanced non-squamous non-small cell lung cancer (NSCLC) patients. Two parallel multiplexed approaches were performed based on DNA sequencing and direct digital detection of RNA with nCounter® technology to evaluate gene mutations and fusions. The results were used to guide genotype-directed therapies and patient outcomes were collected. A total of 224 advanced non-squamous NSCLC patients were prospectively included in the study. Overall, 85% of samples were successfully characterized at DNA and RNA levels and oncogenic drivers were found in 68% of patients, with KRAS, EGFR, METΔex14, BRAF, and ALK being the most frequent (31%, 19%, 5%, 4%, and 4%, respectively). Among all patients with complete genotyping results and follow-up data (n = 156), the median overall survival (OS) was 1.90 years (confidence interval (CI) 95% 1.69-2.10) for individuals harbouring an actionable driver treated with a matched therapy, compared with 0.59 years (CI 95% 0.39-0.79) in those not eligible for any targeted therapy and 0.61 years (CI 95% 0.12-1.10) in patients with no drivers identified (p < 0.001). Integrating DNA and RNA multiplexing technologies into the routine molecular testing of advanced NSCLC patients is feasible and useful and highlights the necessity of widespread integrating comprehensive molecular diagnosis into lung cancer care.
Collapse
Affiliation(s)
- Elba Marin
- Division of Medical Oncology, Hospital Clínic, 08036 Barcelona, Spain; (E.M.); (E.C.-R.); (R.R.); (A.A.); (N.V.); (M.R.-M.); (A.R.); (A.P.)
- Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d’Investigacions Biomèdiques August Pi I Sunyer, 08036 Barcelona, Spain;
- Unitat Funcional de Tumors Toràcics, Hospital Clínic, 08036 Barcelona, Spain; (M.S.); (I.V.)
| | - Cristina Teixido
- Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d’Investigacions Biomèdiques August Pi I Sunyer, 08036 Barcelona, Spain;
- Unitat Funcional de Tumors Toràcics, Hospital Clínic, 08036 Barcelona, Spain; (M.S.); (I.V.)
- Division of Pathology, Hospital Clínic, 08036 Barcelona, Spain; (M.G.); (S.A.); (P.J.); (A.M.)
| | - Elena Carmona-Rocha
- Division of Medical Oncology, Hospital Clínic, 08036 Barcelona, Spain; (E.M.); (E.C.-R.); (R.R.); (A.A.); (N.V.); (M.R.-M.); (A.R.); (A.P.)
| | - Roxana Reyes
- Division of Medical Oncology, Hospital Clínic, 08036 Barcelona, Spain; (E.M.); (E.C.-R.); (R.R.); (A.A.); (N.V.); (M.R.-M.); (A.R.); (A.P.)
- Unitat Funcional de Tumors Toràcics, Hospital Clínic, 08036 Barcelona, Spain; (M.S.); (I.V.)
| | - Ainara Arcocha
- Division of Medical Oncology, Hospital Clínic, 08036 Barcelona, Spain; (E.M.); (E.C.-R.); (R.R.); (A.A.); (N.V.); (M.R.-M.); (A.R.); (A.P.)
- Unitat Funcional de Tumors Toràcics, Hospital Clínic, 08036 Barcelona, Spain; (M.S.); (I.V.)
| | - Nuria Viñolas
- Division of Medical Oncology, Hospital Clínic, 08036 Barcelona, Spain; (E.M.); (E.C.-R.); (R.R.); (A.A.); (N.V.); (M.R.-M.); (A.R.); (A.P.)
- Unitat Funcional de Tumors Toràcics, Hospital Clínic, 08036 Barcelona, Spain; (M.S.); (I.V.)
| | - MªCarmen Rodríguez-Mues
- Division of Medical Oncology, Hospital Clínic, 08036 Barcelona, Spain; (E.M.); (E.C.-R.); (R.R.); (A.A.); (N.V.); (M.R.-M.); (A.R.); (A.P.)
- Unitat Funcional de Tumors Toràcics, Hospital Clínic, 08036 Barcelona, Spain; (M.S.); (I.V.)
| | - Carlos Cabrera
- Division of Medical Oncology, Instituto Oncologico Dr. Rosell, Teknon Hospital, 08028 Barcelona, Spain;
| | - Marcelo Sánchez
- Unitat Funcional de Tumors Toràcics, Hospital Clínic, 08036 Barcelona, Spain; (M.S.); (I.V.)
- Division of Thoracic Radiology, Hospital Clínic Barcelona, 08036 Barcelona, Spain
| | - Ivan Vollmer
- Unitat Funcional de Tumors Toràcics, Hospital Clínic, 08036 Barcelona, Spain; (M.S.); (I.V.)
- Division of Thoracic Radiology, Hospital Clínic Barcelona, 08036 Barcelona, Spain
| | - Sergi Castillo
- Division of Medical Oncology, Hospital General de Granollers, 08402 Barcelona, Spain; (S.C.); (S.M.)
| | - Silvia Muñoz
- Division of Medical Oncology, Hospital General de Granollers, 08402 Barcelona, Spain; (S.C.); (S.M.)
| | - Ivana G. Sullivan
- Division of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain;
| | - Adela Rodriguez
- Division of Medical Oncology, Hospital Clínic, 08036 Barcelona, Spain; (E.M.); (E.C.-R.); (R.R.); (A.A.); (N.V.); (M.R.-M.); (A.R.); (A.P.)
| | - Mireia Garcia
- Division of Pathology, Hospital Clínic, 08036 Barcelona, Spain; (M.G.); (S.A.); (P.J.); (A.M.)
| | - Silvia Alos
- Division of Pathology, Hospital Clínic, 08036 Barcelona, Spain; (M.G.); (S.A.); (P.J.); (A.M.)
| | - Pedro Jares
- Division of Pathology, Hospital Clínic, 08036 Barcelona, Spain; (M.G.); (S.A.); (P.J.); (A.M.)
- Molecular Biology Core Facility, Hospital Clínic, 08036 Barcelona, Spain
| | - Antonio Martinez
- Division of Pathology, Hospital Clínic, 08036 Barcelona, Spain; (M.G.); (S.A.); (P.J.); (A.M.)
| | - Aleix Prat
- Division of Medical Oncology, Hospital Clínic, 08036 Barcelona, Spain; (E.M.); (E.C.-R.); (R.R.); (A.A.); (N.V.); (M.R.-M.); (A.R.); (A.P.)
- Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d’Investigacions Biomèdiques August Pi I Sunyer, 08036 Barcelona, Spain;
- Department of Medicine, University of Barcelona, 08036 Barcelona, Spain
| | - Miguel Ángel Molina-Vila
- Laboratory of Oncology, Pangaea Oncology, Quirón Dexeus University Hospital, 08028 Barcelona, Spain;
| | - Noemi Reguart
- Division of Medical Oncology, Hospital Clínic, 08036 Barcelona, Spain; (E.M.); (E.C.-R.); (R.R.); (A.A.); (N.V.); (M.R.-M.); (A.R.); (A.P.)
- Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d’Investigacions Biomèdiques August Pi I Sunyer, 08036 Barcelona, Spain;
- Unitat Funcional de Tumors Toràcics, Hospital Clínic, 08036 Barcelona, Spain; (M.S.); (I.V.)
| |
Collapse
|
24
|
Padmanabhan S, Lanz TA, Gorman D, Wolfe M, Joyce A, Cabrera C, Lawrence-Henderson R, Levers N, Joshi N, Ma TC, Liong C, Narayan S, Alcalay RN, Hutten SJ, Baptista MA, Merchant K. An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson's Disease and G2019S LRRK2 Cohorts. J Parkinsons Dis 2020; 10:623-629. [PMID: 32007961 PMCID: PMC7242833 DOI: 10.3233/jpd-191786] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Accepted: 01/04/2020] [Indexed: 12/28/2022]
Abstract
The phosphorylated form of LRRK2, pS935 LRRK2, has been proposed as a target modulation biomarker for LRRK2 inhibitors. The primary aim of the study was to characterize and qualify this biomarker for therapeutic trials of LRRK2 inhibitors in Parkinson's disease (PD). To this end, analytically validated assays were used to monitor levels of pS935 LRRK2 and total LRRK2 in peripheral blood mononuclear cells (PBMCs) from the following donor groups: healthy controls, idiopathic PD, and G2019S carriers with and without PD. Neither analyte correlated with age, gender, or disease severity. While total LRRK2 levels were similar across the four groups, there was a significant reduction in pS935 LRRK2 levels in disease-manifesting G2019S carriers compared to idiopathic PD. In aggregate, these data indicate that phosphorylation of LRRK2 at S935 may reflect a state marker for G2019S LRRK2-driven PD, the underlying biology for which requires investigation in future studies. This study also provides critical foundational data to inform the integration of pS935 and total LRRK2 levels as biomarkers in therapeutic trials of LRRK2 kinase inhibitors.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Najah Levers
- Department of Neurology, Columbia University, NY, USA
| | - Neal Joshi
- Department of Neurology, Columbia University, NY, USA
| | - Thong C. Ma
- Department of Neurology, Columbia University, NY, USA
| | | | | | | | | | | | | |
Collapse
|
25
|
Matas-García A, Milisenda JC, Selva-O'Callaghan A, Prieto-González S, Padrosa J, Cabrera C, Reguart N, Castrejón N, Solé M, Ros J, Trallero-Araguas E, Antoniol MN, Vila-Pijoan G, Grau JM. Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern. Autoimmun Rev 2019; 19:102455. [PMID: 31838162 DOI: 10.1016/j.autrev.2019.102455] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2019] [Accepted: 08/01/2019] [Indexed: 11/28/2022]
Abstract
BACKGROUND AND OBJECTIVE Drug-induced myopathy is among the most common causes of muscle disease. An association has recently been described between programmed death-1 (PD-1)/PD-1 ligand (PD-L1) inhibitors and immune-related adverse events (irAE) affecting the muscle. Here, we report the clinical and pathological findings of nine unrelated patients with PD-1 and PD-L1 inhibitors-associated myopathy. METHODS We retrospectively analyzed 317 muscle biopsies performed for diagnostic purposes from January 2017 to June 2019. Patients were attended in two tertiary centers and muscle biopsies were performed and analyzed by two myology experts. Muscle biopsies were frozen in cooled isopenthane, cryostat sectioned and stained. Immunohistochemistry studies were also performed as a routine procedure in our lab. RESULTS We identified 9 patients receiving anti-PD-1 or PD-L1 inhibitors consulting for either muscle weakness, asthenia, myasthenic-like syndrome or other muscle related-symptoms, along with biopsy-proven inflammatory myopathy. One had concomitant myocarditis. In most of the cases muscle biopsy showed a marked phenomenon of necrosis, macrophagy and muscle regeneration with perivascular inflammatory infiltrates with a large component of macrophagic cells. A tendency to perifascicular atrophy was also noticed. The expression of MHC class I antigens predominated in the perifascicular zones. Raised muscle enzymes were detected in 7 patients. CONCLUSION A characteristic clinic-pathological pattern, including a myasthenia gravis-like syndrome plus myositis was found in patients receiving PD-1 and PD-1 L inhibitors. A large component of macrophages resembling granulomas seems to be the pathological hallmark of the syndrome. Further information is required to understand the wide spectrum of immune-related adverse events involving the muscle during or after treatment with anti-PD-1 inhibitors, but the pathological picture seems to be characteristic.
Collapse
Affiliation(s)
- Ana Matas-García
- Muscle Research Unit, Internal Medicine Service, Hospital Clínic de Barcelona (HCB), Universidad de Barcelona, Center for Biomedical Research on Rare Diseases (CIBERER), Barcelona, Spain
| | - José C Milisenda
- Muscle Research Unit, Internal Medicine Service, Hospital Clínic de Barcelona (HCB), Universidad de Barcelona, Center for Biomedical Research on Rare Diseases (CIBERER), Barcelona, Spain.
| | - Albert Selva-O'Callaghan
- Systemic Autoimmune Diseases Unit, Hospital Universitari Vall d'Hebron (HVH), UniversitatAutònoma de Barcelona, Barcelona, Spain
| | - Sergio Prieto-González
- Department of Autoimmune Diseases, Hospital Clínic de Barcelona, Universitat de Barcelona, Spain
| | - Joan Padrosa
- Muscle Research Unit, Internal Medicine Service, Hospital Clínic de Barcelona (HCB), Universidad de Barcelona, Center for Biomedical Research on Rare Diseases (CIBERER), Barcelona, Spain
| | - Carlos Cabrera
- Medical Oncology Department, Hospital Clínic de Barcelona, Spain
| | - Noemi Reguart
- Medical Oncology Department, Hospital Clínic de Barcelona, Spain
| | | | - Manel Solé
- Pathology Department, Hospital Clínic de Barcelona, Spain
| | - Javier Ros
- Medical Oncology Department, Hospital Universitari Vall d'Hebron (HVH), Barcelona, Spain
| | | | | | - Gemma Vila-Pijoan
- Immunology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | - Josep María Grau
- Muscle Research Unit, Internal Medicine Service, Hospital Clínic de Barcelona (HCB), Universidad de Barcelona, Center for Biomedical Research on Rare Diseases (CIBERER), Barcelona, Spain
| |
Collapse
|
26
|
Teixido C, Cabrera C, Rodríguez A, Arcocha A, Pascual T, Gimenez-Capitan A, Marin E, Reyes R, Aguado C, Martinez-Muñoz A, Viñolas N, Oñate B, Martinez D, Molina-Vila M, Prat A, Reguart N. P2.04-22 Programmed Death 1-mRNA Expression Predicts Benefit to Anti-PD1 Monotherapy in a Prospective Cohort of Advanced NSCLC. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
27
|
Casas F, Sánchez D, Boada M, Munoz D, Cabrera C, Martin R, Martinez D, Paredes P, Vollmer I, Cortes K, Barreto T, Oses G, Parera M, Castillo S. P2.18-19 Radiological and Pathological Response to the Induction of Surgery in the NSCLC Stage III. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1973] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
28
|
Sarria G, Sperk E, Xiaodi H, Sarria G, Wenz F, Brehmer S, Fu B, Min S, Zhang H, Qin S, Qiu X, Abo-Madyan Y, Hänggi D, Martinez D, Cabrera C, Giordano F. Intraoperative Radiotherapy for Glioblastoma: An International Pooled Analysis. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.2308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
29
|
Cabrera C. A-56 Predicting Performance on the Raven’s Matrices from the Findings of the Boston Longitudinal MIDUS Study. Arch Clin Neuropsychol 2019. [DOI: 10.1093/arclin/acz034.56] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Objective
To examine the relationship between different cognitive measures and Raven’s Progressive Matrices (RPM) during midlife.
Methods
Data was derived from a de-identified MIDUS-II database (n = 328, 57.8% male, Mage = 48.14, Meducation = 15.8, 93% Caucasian). All participants were administered cognitive tests consisting of several measures of cognitive ability (Trails-B, Vocabulary, Forward & Backward-Digit-Span, and Digit-Symbol-Substitution-Test (DSST)) and RPM.
Results
Pearson correlations were conducted between cognitive performance on various measures and performance on RPM. Using a Bonferroni correction across all correlations, p-value was set at .001. Better performance on RPM was negatively associated with Trails-B (r(139) = -.446,p = .001) and positively associated with Vocabulary (r(168) = .424,p = .001), Forward-Digit-Span (r(168) = .318,p = .001), Backward-Digit-Span (r(166) = .257,p = .001), DSST (r(166) = .516,p = .001).
Conclusions
Results suggest that DSST is the strongest predictor of RPM performance, followed by Trails-B. Reasons for the strong DSST correlation suggest the shared component of sustained attention, processing speed, working memory and set shifting. A moderate association with Trails-B implies the shared components of visual-conceptualization, visual motor tracking, and working memory. Both DSST and Trails-B not only require working memory, but also visuospatial skills, suggesting the use of high-level processes may be required for successful performance on the RPM. Moreover, visuospatial skills may be more strongly related to fluid intelligence than other abilities. This suggests that visualization skills to perceive and mentally reproduce patterns, mental rotation, and flexibility of closure to detect a stimulus hidden within a complex figure are all essential in RPM performance. Future studies should focus on gender and age differences in relation to visuospatial skills, specifically the age at which these differences occur.
Collapse
|
30
|
Teixido C, Marin E, Aguado C, Pare L, Gimenez-Capitan A, Lopez-Prades S, Cardona AF, Cabrera C, Gonzalvo E, Lopez L, Roman R, Martinez D, Sullivan I, Jares P, Prat A, Molina-Vila MA, Reguart N. Abstract 131: Concordance of mRNA expression (nCounter) and protein expression (IHC) for the detection of PD-L1 in patients with advanced non-small cell lung cancer (NSCLC). Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: PD-L1 immunohistochemistry (IHC) staining is currently accepted as the gold-standard biomarker for immune therapy in advanced non-small cell lung cancer (NSCLC). However, the use of various antibodies and cut-offs as well as certain degree of subjectivity in pathological evaluation has overshadowed the clear-cut predictive performance of PD-L1 expression. Multiplexed technologies can be of help in this setting providing an objective measurement of PD-L1 levels. On the other hand, gene expression signatures incorporating not only PD-L1 but also other components of the stroma might better capture the immune-context of the molecular heterogeneity of NSCLC tumors. nCounter gene expression technology is an alternative method to measure PD-L1 gene expression by digital counting proving a direct measurement of mRNA levels.
Methods: A 7-gene ‘immune signature’ comprising CD4, CD8, programmed cell death-1 (PD-1), programmed death-ligand 1 (PD-L1), interferon gamma (IFNG), granzyme M (GZMM) and forkhead box P3 (FOXP3) were included in a customized nCounter panel (NanoString Technologies), used in our institution on a routine basis to simultaneously screen for relevant oncogenic-drivers (ALK, ROS1, RET, NTRK1 gene fusions and METΔ14 mutation). Total RNA obtained from formalin-fixed paraffin embedded (FFPE) samples was used for PD-L1 digital counting (nCounter) which was normalised with six housekeeping genes (ACTB, MRPL19, PSMC4, RPLP0, SF3A1, GAPDH) and compared with PD-L1 protein IHC evaluation using whole tissue section with 22C3 monoclonal mouse anti-PD-L1 antibody measured on tumor cells.
Results: A total of 425 FFPE samples from advanced NSCLC were analyzed with the nCounter panel. Among them, 25 samples were not evaluable (5.9%). PD-L1 IHC was available for 163 FFPE samples and were compared with nCounter PD-L1 expression results. By IHC, 63/163 samples (38.65%) were scored as negative for PD-L1 protein expression, whereas 100/163 (61.35%) were evaluated as positive. Among positive, 62 (38.04%) and 38 (23.31%) presented a moderate (≥ 1-49%) and high PD-L1 staining (≥50%) respectively. Using an appropriate cut-off value (IHC≥1%), PD-L1 mRNA expression levels correlated with PD-L1 IHC evaluation with a 76% of concordance and a 0.755 Cohen’s kappa (confidence interval 95% 0.651- 0.858). Unsupervised clustering across of mRNA expression data from 395 samples using the seven-immune-related genes and correlations between each immune gene were performed and a high correlation was found between PD-1 and FOXP3 (r=0.9) and PD-1 with GZMM (r=0.8).
Conclusions: PD-L1 mRNA gene expression shows promising in predicting PD-L1 protein expression in NSCLC. Further clinical validation is ongoing to confirm if PD-L1 gene expression by nCounter can be an alternative to IHC to select patients’ candidates for immune check-point inhibitors.
Citation Format: Cristina Teixido, Elba Marin, Cristina Aguado, Laia Pare, Ana Gimenez-Capitan, Sandra Lopez-Prades, Andres Felipe Cardona, Carlos Cabrera, Elena Gonzalvo, Laura Lopez, Ruth Roman, Daniel Martinez, Ivana Sullivan, Pedro Jares, Aleix Prat, Miguel Angel Molina-Vila, Noemi Reguart. Concordance of mRNA expression (nCounter) and protein expression (IHC) for the detection of PD-L1 in patients with advanced non-small cell lung cancer (NSCLC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 131.
Collapse
Affiliation(s)
| | | | - Cristina Aguado
- 2Hospital Universitario Quirón Dexeus, Laboratory of Oncology, Pangaea Oncology, Barcelona, Spain
| | | | - Ana Gimenez-Capitan
- 2Hospital Universitario Quirón Dexeus, Laboratory of Oncology, Pangaea Oncology, Barcelona, Spain
| | | | | | | | | | - Laura Lopez
- 4Hospital Santa Creu i Sant Pau, Barcelona, Spain
| | - Ruth Roman
- 2Hospital Universitario Quirón Dexeus, Laboratory of Oncology, Pangaea Oncology, Barcelona, Spain
| | | | | | | | | | - Miguel Angel Molina-Vila
- 2Hospital Universitario Quirón Dexeus, Laboratory of Oncology, Pangaea Oncology, Barcelona, Spain
| | | |
Collapse
|
31
|
Esteban CA, Teixidó C, Román R, Capitán AMG, Cabrera C, García M, Casas CDMDL, Arcocha A, Rodriguez S, Reyes R, Marín E, Rosado AP, Karachaliou N, Prat A, Rosell R, Martinez-Bueno A, Molina-Vila MA, Reguart N. Abstract 4905: Comprehensive characterization of MET alterations in a large cohort of 610 advanced non-small cell lung cancer patients. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-4905] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: A variety of alterations in MET have been described in advanced non-small cell lung cancer (NSCLC) patients, including gene amplification, protein overexpression, splicing variants and point mutations. MET alterations are receiving increasing attention as targets in precision medicine, and several clinical trials of anti-MET agents are ongoing in NSCLC.
Methods: A cohort of 610 patients with stage IIIb-IV NSCLC from two institutions was retrospectively analyzed for MET alterations by next-generation sequencing (NGS) (Ion Torrent PGM® or GeneReader®), nCounter, reverse transcriptase polymerase chain reaction (RT-PCR) or immunohistochemistry (IHC) during a 2-year period. Patients positive for MET amplification by NGS or MET overexpression by nCounter and/or IHC were submitted to fluorescence in situ hybridization (FISH). Representative patients positive for MET exon 14-skipping (METΔex14) mutations by nCounter and/or RT-PCR were confirmed by sequencing exons 13-15 of the METgene.
Results: Overall, MET alterations were found in 116/610 patients (19%). Some patients had ≥2 MET aberrations. The most frequent finding was MET overexpression (58/333; 17.6%), followed by METΔex14 (31/610; 5.1%) and MET point mutations (3/129; 2.3%). Regarding MET amplification, it was found in 24/157 patients (15.3%). MET positivity by IHC (3+, >50%) showed a 90.8% concordance with MET mRNA overexpression by nCounter, with a 0.768 Cohen’s kappa (confidence interval, CI 95% 0.575-0.961). A moderate agreement between RT-PCR and nCounter was found for METΔex14 (Cohen’s kappa 0.629; CI 95% 0.434-0.825). METamplification by FISH was found in the subset of MET-overexpressing patients with the highest mRNA levels by nCounter. Interestingly, a patient with a concomitant EGFR mutation and MET overexpression derived two years clinical benefit from crizotinib.
Conclusions: MET aberrations are present in 19% of advanced NSCLC patients and represent one of the most frequent targetable alterations in this malignancy. A comprehensive testing of MET alterations in advanced NSCLC patients, including NGS and nCounter techniques, is needed to identify a broader number of patients’ candidates for targeted therapies.
Citation Format: Cristina Aguado Esteban, Cristina Teixidó, Ruth Román, Ana María Gimenez Capitán, Carlos Cabrera, Mireia García, Clara D. Mayo De Las Casas, Ainara Arcocha, Sonia Rodriguez, Roxana Reyes, Elba Marín, Ana Perez Rosado, Niki Karachaliou, Aleix Prat, Rafael Rosell, Alejandro Martinez-Bueno, Miguel Angel Molina-Vila, Noemi Reguart. Comprehensive characterization of MET alterations in a large cohort of 610 advanced non-small cell lung cancer patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4905.
Collapse
Affiliation(s)
| | - Cristina Teixidó
- 2Pathology Department, Hospital Clinic de Barcelona, Barcelona, Spain, Barcelona, Spain
| | - Ruth Román
- 1Pangaea Oncology, Hospital Quiron Dexeus, Barcelona, Spain
| | | | - Carlos Cabrera
- 3Medical Oncology Department, IDIBAPS and Hospital Clinic de Barcelona, Barcelona, Spain, Barcelona, Spain
| | - Mireia García
- 2Pathology Department, Hospital Clinic de Barcelona, Barcelona, Spain, Barcelona, Spain
| | | | - Ainara Arcocha
- 3Medical Oncology Department, IDIBAPS and Hospital Clinic de Barcelona, Barcelona, Spain, Barcelona, Spain
| | | | - Roxana Reyes
- 3Medical Oncology Department, IDIBAPS and Hospital Clinic de Barcelona, Barcelona, Spain, Barcelona, Spain
| | - Elba Marín
- 2Pathology Department, Hospital Clinic de Barcelona, Barcelona, Spain, Barcelona, Spain
| | | | - Niki Karachaliou
- 4Instituto Oncológico Dr. Rosell (IOR), Sagrat Cor Hospital, Barcelona, Spain, Barcelona, Spain
| | - Aleix Prat
- 3Medical Oncology Department, IDIBAPS and Hospital Clinic de Barcelona, Barcelona, Spain, Barcelona, Spain
| | - Rafael Rosell
- 5Catalan Institute of Oncology and Institut d’Investigació en Ciències de la Salut, Germans Trias i Pujol, Badalona, Spain, Barcelona, Spain
| | | | | | - Noemi Reguart
- 3Medical Oncology Department, IDIBAPS and Hospital Clinic de Barcelona, Barcelona, Spain, Barcelona, Spain
| |
Collapse
|
32
|
Bahji A, Hawken ER, Cabrera C, Vazquez G. Is stigma preventing knowledge translation and utilization of electroconvulsive therapy for depression? Acta Psychiatr Scand 2019; 140:85-87. [PMID: 30980536 DOI: 10.1111/acps.13035] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- A Bahji
- Department of Psychiatry, Queen's University, Kingston, ON, Canada.,Department of Public Health Sciences, Queen's University, Kingston, ON, Canada
| | - E R Hawken
- Department of Psychiatry, Queen's University, Kingston, ON, Canada.,Providence Care Hospital, Kingston, ON, Canada
| | - C Cabrera
- Department of Psychiatry, Queen's University, Kingston, ON, Canada.,Providence Care Hospital, Kingston, ON, Canada
| | - G Vazquez
- Department of Psychiatry, Queen's University, Kingston, ON, Canada.,Providence Care Hospital, Kingston, ON, Canada
| |
Collapse
|
33
|
Reyes R, Mayo-de-las-Casas C, Teixidó C, Cabrera C, Marín E, Vollmer I, Jares P, Garzón M, Molina-Vila MÁ, Reguart N. Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report. Clin Lung Cancer 2019; 20:e219-e223. [DOI: 10.1016/j.cllc.2019.02.022] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2018] [Revised: 02/11/2019] [Accepted: 02/21/2019] [Indexed: 02/09/2023]
|
34
|
Sarria G, Cabrera C, Sarria G, Buitrago M, Fuentes Rivera P, Serpa S, Giordano F. PO-1063 Single-fraction low-energy electronic brachytherapy for conjunctival lymphoma. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31483-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
35
|
Sánchez-Villegas A, Cabrera-Suárez B, Molero P, González-Pinto A, Chiclana-Actis C, Cabrera C, Lahortiga-Ramos F, Florido-Rodríguez M, Vega-Pérez P, Vega-Pérez R, Pla J, Calviño-Cabada MJ, Ortuño F, Navarro S, Almeida Y, Hernández-Fleta JL. Preventing the recurrence of depression with a Mediterranean diet supplemented with extra-virgin olive oil. The PREDI-DEP trial: study protocol. BMC Psychiatry 2019; 19:63. [PMID: 30744589 PMCID: PMC6371613 DOI: 10.1186/s12888-019-2036-4] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/07/2018] [Accepted: 01/25/2019] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND The role of dietary patterns in the prevention of unipolar depression has been analyzed in several epidemiological studies. The primary aims of this study are to determine the effectiveness of an extra-olive oil-enriched Mediterranean diet in reducing the recurrence of depression and improving the symptoms of this condition. METHODS Multicenter, two-arm, parallel-group clinical trial. Arm 1, extra-virgin olive oil Mediterranean diet; Arm 2, control group without nutritional intervention. Dieticians are in charge of the nutritional intervention and regular contact with the participants. Contacts are made through our web platform ( https://predidep.es/participantes/ ) or by phone. Recurrence of depression is assessed by psychiatrists and clinical psychologists through clinical evaluations (semi-structured clinical interviews: Spanish SCID-I). Depressive symptoms are assessed with the Beck Depression Inventory. Information on quality of life, level of physical activity, dietary habits, and blood, urine and stool samples are collected after the subject has agreed to participate in the study and once a year. DISCUSSION To the best of our knowledge, the PREDI-DEP trial is the first ongoing randomized clinical trial designed to assess the role of the Mediterranean diet in the prevention of recurrent depression. It could be a cost-effective approach to avoid recurrence and improve the quality of life of these patients. TRIAL REGISTRATION The study has been prospectively registered in the U.S. National Library of Medicine ( https://clinicaltrials.gov ) with NCT number: NCT03081065.
Collapse
Affiliation(s)
- A. Sánchez-Villegas
- 0000 0004 1769 9380grid.4521.2Nutrition Research Group, Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Paseo Blas Cabrera Felipe Físico s/n, 35016 Las Palmas de Gran Canaria, Spain ,0000 0000 9314 1427grid.413448.eBiomedical Research Center Network on Obesity and Nutrition (CIBERobn) Physiopathology of Obesity and Nutrition, Institute of Health Carlos III, Madrid, Spain
| | - B. Cabrera-Suárez
- Psychiatry and Clinical Psychology Service, Hospital General de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain
| | - P. Molero
- 0000 0001 2191 685Xgrid.411730.0Department of Psychiatry and Medical Psychology, University Clinic of Navarra, Pamplona, Spain ,IDISNA (Instituto de Investigación Sanitaria de Navarra), Pamplona, Spain
| | - A. González-Pinto
- Psychiatry and Clinical Psychology Service, Hospital Universitario de Alava, Vitoria, Spain ,0000 0000 9314 1427grid.413448.eBiomedical Research Center Network on Mental Health (CIBERsam), Institute of Health Carlos III, Madrid, Spain
| | | | - C. Cabrera
- Psychiatry and Clinical Psychology Service, Hospital General de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain
| | - F. Lahortiga-Ramos
- 0000 0001 2191 685Xgrid.411730.0Department of Psychiatry and Medical Psychology, University Clinic of Navarra, Pamplona, Spain ,IDISNA (Instituto de Investigación Sanitaria de Navarra), Pamplona, Spain
| | - M. Florido-Rodríguez
- Psychiatry and Clinical Psychology Service, Hospital General de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain
| | - P. Vega-Pérez
- Psychiatry and Clinical Psychology Service, Hospital Universitario de Alava, Vitoria, Spain
| | - R. Vega-Pérez
- Psychiatry and Clinical Psychology Service, Hospital General de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain
| | - J. Pla
- 0000 0001 2191 685Xgrid.411730.0Department of Psychiatry and Medical Psychology, University Clinic of Navarra, Pamplona, Spain ,IDISNA (Instituto de Investigación Sanitaria de Navarra), Pamplona, Spain
| | - M. J. Calviño-Cabada
- Psychiatry and Clinical Psychology Service, Hospital General de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain
| | - F. Ortuño
- 0000 0001 2191 685Xgrid.411730.0Department of Psychiatry and Medical Psychology, University Clinic of Navarra, Pamplona, Spain ,IDISNA (Instituto de Investigación Sanitaria de Navarra), Pamplona, Spain
| | - S. Navarro
- Psychiatry and Clinical Psychology Service, Hospital General de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain
| | - Y. Almeida
- Psychiatry and Clinical Psychology Service, Hospital General de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain
| | - J. L. Hernández-Fleta
- Psychiatry and Clinical Psychology Service, Hospital General de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain
| |
Collapse
|
36
|
Urzúa A, Cabrera C, Carvajal CC, Caqueo-Urízar A. The mediating role of self-esteem on the relationship between perceived discrimination and mental health in South American immigrants in Chile. Psychiatry Res 2019; 271:187-194. [PMID: 30500708 DOI: 10.1016/j.psychres.2018.11.028] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/17/2018] [Revised: 11/13/2018] [Accepted: 11/14/2018] [Indexed: 11/28/2022]
Abstract
Psychological aspects in South-South migration have been little studied. The following study aimed to describe the effect of individual self-esteem as a mediator in the relationship between perceived discrimination and mental health (understood as the presence of anxious and depressive symptomatology) in South American migrants in Chile. We surveyed 853 people, of Peruvian and Colombian nationality, residing in three cities (Arica, Antofagasta and Santiago). Three ad-hoc scales were applied to evaluate the study variables, analyzing the measurement models for each of them using the Confirmatory Factor Analysis method. Subsequently, the hypothesized mediation model is evaluated through Structural Equations (SEM). The results show that discrimination has a positive and direct relationship with both anxiety and depression, and that the effect of interaction between the variables of discrimination, self-esteem and symptoms associated with depression and anxiety, had a simple partial mediating effect. Discrimination would have a positive and minor effect on anxious and depressive symptoms, as it is mediated by self-esteem.
Collapse
Affiliation(s)
- Alfonso Urzúa
- Universidad Católica del Norte, Escuela de Psicología, Avda. Angamos 0610, Antofagasta, Chile.
| | - Carlos Cabrera
- Universidad Católica del Norte, Escuela de Psicología, Avda. Angamos 0610, Antofagasta, Chile.
| | | | | |
Collapse
|
37
|
Lenox M, Solow A, Tran V, Cabrera C, Stripling A. USE IT OR LOSE IT: MORE RECENT SEX AND ITS IMPACT ON OLDER ADULT WELL-BEING. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.1060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- M Lenox
- Nova Southeastern University
| | - A Solow
- Nova Southeastern University
| | - V Tran
- Nova Southeastern University
| | | | | |
Collapse
|
38
|
Remon J, Hendriks LE, Cabrera C, Reguart N, Besse B. Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change? Cancer Treat Rev 2018; 71:47-58. [PMID: 30359792 DOI: 10.1016/j.ctrv.2018.10.006] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2018] [Revised: 10/03/2018] [Accepted: 10/10/2018] [Indexed: 12/12/2022]
Abstract
Immune checkpoint inhibitors (ICIs) have been incorporated in the treatment strategy of advanced non-small cell lung cancer (NSCLC) in first- and second-line setting improving the prognosis of these patients. However, the treatment landscape has been also drastically overturned with the advent of targeted therapies in oncogenic-addicted advanced NSCLC patients. Despite ICIs represent an active and new treatment option for a wide range of advanced NSCLC patients, the efficacy and the optimal place of ICI in the treatment strategy algorithm of oncogenic-addicted tumors remains still controversial, as only a minority of trials with ICI enrol oncogenic-addicted NSCLC patients previously treated with standard therapy. Therefore, there are still several open questions about ICI in oncogenic-driven NSCLC, such as the efficacy and toxicities, which need to be addressed before considering treatment with ICI as a standard approach in this population. It is in this framework, we provide a thorough overview on this currently controversial topic.
Collapse
Affiliation(s)
- J Remon
- Centro Integral Oncología Clara Campal Bacelona, HM-Delfos, Medical Oncology Department, Barcelona, Spain.
| | - L E Hendriks
- Gustave Roussy, Cancer Medicine Department, Villejuif, France; Maastricht University Medical Center+, Pulmonary Diseases Department, GROW - School for Oncology and Developmental Biology, Maastricht, the Netherlands.
| | - C Cabrera
- Hospital Clínic i Provincial de Barcelona, Medical Oncology Department, Barcelona, Spain.
| | - N Reguart
- Hospital Clínic i Provincial de Barcelona, Medical Oncology Department, Barcelona, Spain.
| | - B Besse
- Gustave Roussy, Cancer Medicine Department, Villejuif, France; University Paris-Sud, Orsay, France.
| |
Collapse
|
39
|
Teixidó C, Pare L, Aguado C, Lopez S, Giménez-Capitán A, Cardona A, Cabrera C, Castillo S, Garzón M, Mayo C, Sullivan I, Muñoz S, Castellano G, Jares P, Prat A, Molina-Vila M, Reguart N. P3.04-16 A Seven-Gene Expression Signature Reveals Unique Immune-Phenotypes Related to Major Oncogenic-Drivers in NSCLC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1723] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
40
|
Cabrera C, Harcourt S, Golden C. B - 50The Relationship Between Verbal and Executive Function Measures. Arch Clin Neuropsychol 2018. [DOI: 10.1093/arclin/acy061.126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
41
|
Gilmore M, Harcourt S, Strong A, Cabrera C, Golden C. B - 28How Well do PPVT-4, EVT-2, and NDRT Vocabulary Subtest Predict WAIS-IV Indices and FSIQ. Arch Clin Neuropsychol 2018. [DOI: 10.1093/arclin/acy061.104] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Fornalski N, Tran V, Ramandesh D, Gonzalez C, Cabrera C, Stebbins L, Garcia J, Boix Braga M. A - 05The Effects of Sleep Apnea on Cognitive Deficits in Individuals with Alzheimer’s Disease. Arch Clin Neuropsychol 2018. [DOI: 10.1093/arclin/acy061.05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
43
|
Cedeño Y, Gonzalez S, Cabrera C, Messina OG, Lopez J, de Souza M, Astudillo G. Neurocysticercosis an emerging entity in the city of Buenos Aires. Int J Infect Dis 2018. [DOI: 10.1016/j.ijid.2018.04.3854] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
44
|
Martínez-González C, Casanova C, de-Torres JP, Marín JM, de Lucas P, Fuster A, Cosío BG, Calle M, Peces-Barba G, Solanes I, Agüero R, Feu-Collado N, Alfageme I, Romero Plaza A, Balcells E, de Diego A, Marín Royo M, Moreno A, Llunell Casanovas A, Galdiz JB, Golpe R, Lacárcel Bautista C, Cabrera C, Marin A, Soriano JB, Lopez-Campos JL. Changes and Clinical Consequences of Smoking Cessation in Patients With COPD. Chest 2018; 154:274-285. [DOI: 10.1016/j.chest.2018.02.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2017] [Revised: 12/27/2017] [Accepted: 02/01/2018] [Indexed: 10/18/2022] Open
|
45
|
Casanova C, Celli BR, de-Torres JP, Martínez-Gonzalez C, Cosio BG, Pinto-Plata V, de Lucas-Ramos P, Divo M, Fuster A, Peces-Barba G, Calle-Rubio M, Solanes I, Aguero R, Feu-Collado N, Alfageme I, De Diego A, Romero A, Balcells E, Llunell A, Galdiz J, Marin M, Moreno A, Cabrera C, Golpe R, Lacarcel C, Soriano JB, López-Campos JL, Soler-Cataluña JJ, Marin JM. Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. Eur Respir J 2017; 50:50/5/1701162. [DOI: 10.1183/13993003.01162-2017] [Citation(s) in RCA: 103] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2017] [Accepted: 07/27/2017] [Indexed: 01/21/2023]
Abstract
The impact of blood eosinophilia in chronic obstructive pulmonary disease (COPD) remains controversial.To evaluate the prevalence and stability of a high level of blood eosinophils (≥300 cells·μL–1) and its relationship to outcomes, we determined blood eosinophils at baseline and over 2 years in 424 COPD patients (forced expiratory volume in 1 s (FEV1) 60% predicted) and 67 smokers without COPD from the CHAIN cohort, and in 308 COPD patients (FEV1 60% predicted) in the BODE cohort. We related eosinophil levels to exacerbations and survival using Cox hazard analysis.In COPD patients, 15.8% in the CHAIN cohort and 12.3% in the BODE cohort had persistently elevated blood eosinophils at all three visits. A significant proportion (43.8%) of patients had counts that oscillated above and below the cut-off points, while the rest had persistent eosinophil levels <300 cells·μL–1. A similar eosinophil blood pattern was observed in controls. Exacerbation rates did not differ in patients with and without eosinophilia. All-cause mortality was lower in patients with high eosinophils compared with those with values <300 cells·μL–1 (15.8% versus 33.7%; p=0.026).In patients with COPD, blood eosinophils ≥300 cells·μL–1 persisting over 2 years was not a risk factor for COPD exacerbations. High eosinophil count was associated with better survival.
Collapse
|
46
|
Gerodias F, Cabrera C, Suaco D, Datukan J, Ongjoco E, Peralta E. P4358Angiotensin-converting enzyme inhibitors for the primary prevention of heart failure among adult patients on anthracycline-based chemotherapy: a meta-analysis. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.p4358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
47
|
Abstract
Green tea has been consumed for centuries in Japan, China and Morocco.
Collapse
Affiliation(s)
- S. Pastoriza
- Departamento de Nutrición y Bromatología
- Facultad de Farmacia
- Campus de Cartuja S/N
- 18071
- Universidad de Granada
| | - M. Mesías
- Instituto de Ciencia y Tecnología de Alimentos y Nutrición (ICTAN-CSIC)
- Madrid
- Spain
| | - C. Cabrera
- Departamento de Nutrición y Bromatología
- Facultad de Farmacia
- Campus de Cartuja S/N
- 18071
- Universidad de Granada
| | - J. A. Rufián-Henares
- Departamento de Nutrición y Bromatología
- Facultad de Farmacia
- Campus de Cartuja S/N
- 18071
- Universidad de Granada
| |
Collapse
|
48
|
Cabrera C, Arranz M, Calnge MS, Salas A, Tarroch X, Ibañez L, Garcia A, Jimenez SG, Campayo M, Cirera L. Genetic influence of EGFR-PI3K-mTOR pathway and other loci in triple-negative breast cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw363.57] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
49
|
Wilson DH, Rissin DM, Kan CW, Fournier DR, Piech T, Campbell TG, Meyer RE, Fishburn MW, Cabrera C, Patel PP, Frew E, Chen Y, Chang L, Ferrell EP, von Einem V, McGuigan W, Reinhardt M, Sayer H, Vielsack C, Duffy DC. The Simoa HD-1 Analyzer. ACTA ACUST UNITED AC 2016; 21:533-47. [DOI: 10.1177/2211068215589580] [Citation(s) in RCA: 216] [Impact Index Per Article: 27.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2015] [Indexed: 01/27/2023]
|
50
|
Cabrera C, Casanova C, Martín Y, Mirabal V, Sánchez MDC, Álvarez F, Juliá G, Cabrera-Navarro P, García-Bello MÁ, Marín JM, de-Torres JP, Divo M, Celli B. Agreement between a simple dyspnea-guided treatment algorithm for stable COPD and the GOLD guidelines: a pilot study. Int J Chron Obstruct Pulmon Dis 2016; 11:1217-22. [PMID: 27354780 PMCID: PMC4907482 DOI: 10.2147/copd.s100853] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Introduction Guidelines recommendations for the treatment of COPD are poorly followed. This could be related to the complexity of classification and treatment algorithms. The purpose of this study was to validate a simpler dyspnea-based treatment algorithm for inhaled pharmacotherapy in stable COPD, comparing its concordance with the current Global Initiative for Obstructive Lung Disease (GOLD) guideline. Methods We enrolled patients who had been diagnosed with COPD in three primary care facilities and two tertiary hospitals in Spain. We determined anthropometric data, forced expiratory volume in the 1st second (percent), exacerbations, and dyspnea based on the modified Medical Research Council scale. We evaluated the new algorithm based on dyspnea and exacerbations and calculated the concordance with the current GOLD recommendations. Results We enrolled 100 patients in primary care and 150 attending specialized care in a respiratory clinic. There were differences in the sample distribution between cohorts with 41% vs 26% in grade A, 16% vs 12% in grade B, 16% vs 22% in grade C, and 27% vs 40% in grade D for primary and respiratory care, respectively (P=0.005). The coincidence of the algorithm with the GOLD recommendations in primary care was 93% and 91.8% in the respiratory care cohort. Conclusion A simple dyspnea-based treatment algorithm for inhaled pharmacotherapy of COPD could be useful in the management of COPD patients and concurs very well with the recommended schema suggested by the GOLD initiative.
Collapse
Affiliation(s)
- Carlos Cabrera
- University Hospital of Gran Canaria Dr Negrín, Respiratory Service, Las Palmas de Gran Canaria, Spain
| | - Ciro Casanova
- University Hospital Nuestra Señora de la Candelaria, Respiratory Service, Santa Cruz de Tenerife, Spain
| | - Yolanda Martín
- Arucas Health Center, Primary Care Las Palmas de Gran Canaria, Spain
| | - Virginia Mirabal
- Arucas Health Center, Primary Care Las Palmas de Gran Canaria, Spain
| | | | - Felisa Álvarez
- La Feria Health Center, Primary Care Las Palmas de Gran Canaria, Spain
| | - Gabriel Juliá
- University Hospital of Gran Canaria Dr Negrín, Respiratory Service, Las Palmas de Gran Canaria, Spain
| | - Pedro Cabrera-Navarro
- University Hospital of Gran Canaria Dr Negrín, Respiratory Service, Las Palmas de Gran Canaria, Spain
| | - Miguel Ángel García-Bello
- University Hospital of Gran Canaria Dr Negrín, Investigation Unit, Las Palmas de Gran Canaria, Spain
| | - José María Marín
- University Hospital Miguel Servet, Respiratory Service, Zaragoza, Spain
| | | | - Miguel Divo
- Brigham and Women's Hospital, Pulmonary and Critical Care Service, Boston, MA, USA
| | - Bartolomé Celli
- Brigham and Women's Hospital, Pulmonary and Critical Care Service, Boston, MA, USA
| |
Collapse
|